Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 6682. Отображено 100.
02-02-2012 дата публикации

Cancer therapy based on tumor associated antigens derived from cyclin d1

Номер: US20120027684A1
Автор: Harpreet Singh, Steffen Walter, Toni Weinschenk
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Подробнее
Номер записи: 1
17-05-2012 дата публикации

Superoxide dismutase variants and methods of use thereof

Номер: US20120121568A1
Автор: Danica Chen, Xiaolei Qiu
Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.

Подробнее
Номер записи: 2
17-05-2012 дата публикации

Test for Predicting Neutralization of Asparaginase Activity

Номер: US20120121570A1
Автор: Yann Godfrin
Принадлежит: Individual

Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.

Подробнее
Номер записи: 3
05-07-2012 дата публикации

Use of pkc-zeta as a breast cancer tumorigenic biomarker as well as a target for treatment of breast cancer

Номер: US20120171219A1
Автор: Diondra D. Hill, Mildred Acevedo-Duncan
Принадлежит: UNIVERSITY OF SOUTH FLORIDA, US Department of Veterans Affairs VA

The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.

Подробнее
Номер записи: 4
13-09-2012 дата публикации

Methods and systems associated with detection of fatty acid elongation in a cell

Номер: US20120231470A1
Автор: David A. Tirrell, Janek Szychowski, Sungjin Park
Принадлежит: California Institute of Technology CalTech

Methods and systems to identify compounds capable of altering a fatty acid elongation pathway and for identifying conditions under which fatty acids elongation can occur in a cell are described. The methods and systems comprise labeled fatty acid precursors and cells capable of elongating fatty acids. Methods for providing suitable components of an assay for identifying compounds capable of altering a fatty acid elongation pathway are described.

Подробнее
Номер записи: 5
02-05-2013 дата публикации

Inhibition of AXL Signaling in Anti-Metastatic Therapy

Номер: US20130108644A1
Автор: Amato J. Giaccia, Douglas Jones, Erinn Bruno Rankin, Jennifer R. Cochran, Katherine Fuh, Mihalis Kariolis, Yu Miao
Принадлежит: Leland Stanford Junior University

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Подробнее
Номер записи: 6
01-08-2013 дата публикации

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy

Номер: US20130195875A1
Автор: Andreas Bergmann
Принадлежит: ADRENOMED AG

Subject matter of the present invention is an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold wherein said antibody or said fragment or scaffold is a non-neutralizing antibody, antibody fragment or non-Ig scaffold, respectively. Subject matter of the present invention is also an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in a treatment of a chronic or acute disease wherein said antibody or fragment or scaffold is: an ADM stabilizing antibody or an adrenomedullin stabilizing antibody fragment or an ADM stabilizing non-Ig scaffold that enhances the t 1/2 half retention time of adrenomedullin in serum, blood, plasma at least 10%, preferably at least, 50%, more preferably >50%, most preferably 100% and/or wherein said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold blocks the bioactivity of ADM to not more than 80%, or not more than 50%.

Подробнее
Номер записи: 7
12-09-2013 дата публикации

Lmcd1 cancer markers and methods for their use

Номер: US20130239239A1
Автор: C-Y Chang, Y-S Jou
Принадлежит: Academia Sinica

The present invention provides LMCD1 cancer markers, and methods, compositions, and kits for their use. The invention also provides expression vectors, host cells, and transgenic animals comprising one or more LMCD1 mutations, and methods for their use in characterizing, diagnosing, and treating cancers, and for identifying potential therapeutics. The invention also provides cancer therapeutics.

Подробнее
Номер записи: 8
26-09-2013 дата публикации

Procalcitonin gene expression as a precise biomarker of aging process

Номер: US20130252254A1
Автор: Mehmet Ali Soylemez
Принадлежит: Individual

The invention relates to a method for diagnosis and/or complications and/or risk assessment of aging, in particular of aging process, wherein a determination of the marker procalcitonin (PCT: SEQ ID No. 1) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient within normal value ranges of leucocytes under investigation. The invention further relates to invent new drugs, a diagnostic device and a kit for carrying out said method.

Подробнее
Номер записи: 9
24-10-2013 дата публикации

Oxidative stress responsive apoptosis inducing protein eif5a

Номер: US20130280268A1
Автор: Kimie Murayama, Tsutomu Fujimura, Yoshinori Seko
Принадлежит: Individual

Secreted eIF5A protein which is useful for diagnosis, prevention, and treatment of various diseases induced by an oxidative stress.

Подробнее
Номер записи: 10
07-11-2013 дата публикации

Nucleic acid construct for expression of oxidative stress indicator and use thereof

Номер: US20130298263A1
Автор: Daisuke Oikawa, Takao Iwawaki
Принадлежит: RIKEN Institute of Physical and Chemical Research

The present invention provides a nucleic acid construct for expressing an oxidative stress indicator comprising: a nucleic acid sequence encoding an Nrf2 protein-derived partial protein that comprises at least an Neh2 domain sequence and substantially lacks or is functionally deficient in an Neh1 domain sequence or an Neh1-Neh3 domain sequence; a stress-inducible promoter sequence positioned upstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein; and a nucleic acid sequence encoding a protein capable of generating a detectable signal, the nucleic acid sequence being positioned downstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein. The present invention also provides a method for measuring oxidative stress and a method for screening for an anti-oxidative stress agent, using the nucleic acid construct.

Подробнее
Номер записи: 11
02-01-2014 дата публикации

Methods and compositions for targeting sites of neovascular growth

Номер: US20140004040A1
Автор: Anka N. Veleva, Cam Patterson
Принадлежит: North Carolina State University, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Compositions and methods for targeted delivery to and detection of sites of neovascular growth, including tumor vasculature, are provided. Compositions include polypeptides conjugated to or complexed with a bioactive compound, wherein the polypeptide is capable of binding to an OEC or a circulating progenitor thereof. Methods for identifying additional polypeptides with the same binding characteristics are further provided. Methods for targeted delivery of a bioactive compound to a site of neovascular growth are provided in which polypeptides capable of binding OECs or progenitors thereof are conjugated to or complexed with the bioactive compound and administered to a subject in need thereof. Methods for detecting neovascular growth are also provided, wherein the polypeptides conjugated to or complexed with a detectable label are administered to a subject and the label is detected.

Подробнее
Номер записи: 12
16-01-2014 дата публикации

Superoxide Dismutase Variants and Methods of Use Thereof

Номер: US20140017221A1
Автор: Danica Chen, Xiaolei Qiu
Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.

Подробнее
Номер записи: 13
06-02-2014 дата публикации

Depleted anti-staphylococcal enterotoxins polyclonal antibodies, preparation and uses thereof

Номер: US20140037651A1
Автор: Charline Barasino, Daniel Keller, Gilles Prévost, Khaldoun Masoud
Принадлежит: Universite De Strasbourg

The present invention relates to the preparation of a set of depleted polyclonal antibodies, each depleted polyclonal antibody being raised against one specific staphylococcal enterotoxin, and its use for multiplex detection.

Подробнее
Номер записи: 14
06-02-2014 дата публикации

Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor

Номер: US20140039010A1
Автор: Bum Joon Park, Gyu Yong Song, Ji Hyun Lee, Nam Chul Ha, Su Jin Lee, Youn Sang Jung
Принадлежит: University Industry Cooperation Foundation of Pusan National University

Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.

Подробнее
Номер записи: 15
13-02-2014 дата публикации

Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii

Номер: US20140044720A1
Автор: Dimiter S. Dimitrov, QI Zhao, Zhongyu Zhu
Принадлежит: US Department of Health and Human Services

Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.

Подробнее
Номер записи: 16
07-01-2016 дата публикации

Biomarkers for inflammatory disease and methods of using same

Номер: US20160000936A1
Автор: Carolyn Cuff, Jeffrey W. Voss, Melanie C. Ruzek
Принадлежит: AbbVie Inc

The invention provides methods for predicting the efficacy of anti-TNF and anti-IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-1β, IL-1Ra, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCR1, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject.

Подробнее
Номер записи: 17
03-01-2019 дата публикации

Methods and Monitoring of Treatment with a WNT Pathway Inhibitor

Номер: US20190000970A1
Автор: DUPONT JAKOB, STAGG Robert J.
Принадлежит: OncoMed Pharmaceuticals, Inc.

Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity. 184-. (canceled)85. A method for reducing a skeletal-related side effect and/or toxicity in a human subject having cancer and receiving treatment with a Wnt pathway inhibitor for the cancer , comprising:(a) administering a therapeutically effective amount of a Wnt pathway inhibitor to the subject;(b) determining the level of collagen type 1 cross-linked C-telopeptide (β-CTX) in a sample from the subject after the administration of the Wnt pathway inhibitor; and(c) administering to the subject a therapeutically effective amount of a bisphosphonate if the level of β-CTX in the sample is higher than a predetermined level of the β-CTX; andwherein the Wnt pathway inhibitor is a FZD antagonist or a Wnt antagonist.86. The method of claim 85 , wherein the FZD antagonist is a FZD binding agent.87. The method of claim 86 , wherein the FZD binding agent is an antibody.88. The method of claim 85 , wherein the Wnt antagonist is a Wnt binding agent.89. The method of claim 88 , wherein the Wnt binding agent is an antibody or a polypeptide comprising a FZD soluble receptor.90. The method of claim 88 , wherein the Wnt binding agent comprises a Fri domain of a human FZD protein claim 88 , or a fragment or variant of the Fri domain that binds one or more human Wnt proteins.91. The method of claim 85 , wherein the sample is blood claim 85 , serum claim 85 , or plasma.92. The method of claim 85 , wherein the predetermined level of β-CTX is determined at an earlier timepoint claim 85 , at an initial screening claim 85 , and/or prior to treatment.93. The method of claim 85 , wherein the level of β-CTX in the sample is at least two-fold higher than the predetermined level of the β-CTX.94. The method of claim 85 , wherein the skeletal-related side effect and/or toxicity ...

Подробнее
Номер записи: 18
06-01-2022 дата публикации

CD146 AND USES THEREOF AS A BIOMARKER AND AS A THERAPEUTIC TARGET IN THE DIAGNOSIS AND TREATMENT OF FIBROSIS

Номер: US20220003784A1
Автор: BARDIN NATHALIE, BERTAUD ALEXANDRINE, BLOT-CHABAUD MARCEL, CHADJICHRISTOS CHRISTOS, DIGNAT-GEORGE FRANÇOISE, GUILLET BENJAMIN, HACHE GUILLAUME, LEROYER AURÉLIE, Thiemermann Christoph
Принадлежит:

The present invention relates to the field of medicine and in particular to the diagnostic and treatment of fibrosis. More particularly, the invention relates to CD146 and uses thereof as a biomarker in the diagnosis of fibrosis and as a therapeutic target in the treatment of fibrosis. The invention also relates to compositions and methods of detecting predisposition to, of diagnosing, prognosing and/or monitoring fibrosis in a subject. It further relates to CD146 inhibitors, and to compositions comprising a CD146 inhibitor, for use in prevention or treatment of fibrosis in a subject, as well as to compositions, kits and uses thereof in a diagnostic or therapeutic context. 119-. (canceled)20. An in vitro or ex vivo method of:a) detecting predisposition to or of diagnosing and/or prognosing cardiac or renal fibrosis in a subject, the method comprising a step of determining the soluble CD146 protein level of expression in a biological sample of the subject, wherein the soluble CD146 protein is selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; orb) detecting predisposition to or of diagnosing and/or prognosing fibrosis in a subject, the method comprising a step of determining the level of expression of the I5-13 soluble CD146 protein of SEQ ID NO:8 or the I10 soluble CD146 protein of SEQ ID NO:9 in a biological sample of the subject.21. The method according to claim 20 , wherein the method of detecting predisposition to or of diagnosing and/or prognosing cardiac or renal fibrosis comprises the steps of i) determining the soluble CD146 protein expression level in a biological sample of the subject claim 20 , said soluble CD146 protein being selected from SEQ ID NO:1 claim 20 , SEQ ID NO:2 claim 20 , SEQ ID NO:3 claim 20 , SEQ ID NO:4 claim 20 , SEQ ID NO:5 claim 20 , SEQ ID NO:6 and SEQ ID NO:7 claim 20 , ii) comparing the expression level determined at step i) with a reference value and iii) concluding that the ...

Подробнее
Номер записи: 19
02-01-2020 дата публикации

TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS

Номер: US20200002296A1
Автор: Adam Julia
Принадлежит: MIRONID LIMITED

Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) are also described. 112-. (canceled)14. (canceled)16. (canceled)17. The method of wherein the excessive intracellular cyclic AMP signalling is caused by:a. excessive hormone levels produced by an adenoma;b. a gain-of-function gene mutation in a G-protein coupled receptor (GPCR);{'sub': 's', 'c. an activating mutation in the GNAS1 gene, which encodes the α-subunit of the G-protein G; or'}d. a bacterial toxin.18. The method of claim 15 , wherein the disease is cancer.19. The method of claim 18 , wherein the cancer is prostate cancer.20. The method of claim 15 , wherein the disease is:a. pituitary adenoma, Cushing's disease, polycystic kidney disease or polycystic liver disease;b. hyperthyroidism, Jansens's metaphyseal chondrodysplasia, hyperparathyroidism, or familial male-limited precocious puberty;c. McCune-Albright syndrome;d. cholera, whooping cough, anthrax, or tuberculosis;e. HIV, AIDS, or Common Variable Immunodeficiency (CVID);f. melanoma, pancreatic cancer, leukaemia, prostate cancer, adrenocortical tumours, testicular cancer, primary pigmented nodular adrenocortical diseases (PPNAD),or Carney Complex;g. autosomal dominant polycystic kidney disease (ADPKD) or autosomal recessive polycystic kidney disease (ARPKD);h. maturity onset diabetes of young type 5 (MODY5); ori. cardiac hypertrophy.21. The method of claim 20 , wherein the disease is:a. autosomal dominant polycystic kidney disease (ADPKD); orb. autosomal recessive polycystic kidney disease (ARPKD).23. (canceled)24. The method of claim 22 , wherein the disease or disorder is mediated by excessive intracellular cyclic AMP signalling.25. (canceled)26. The method of claim 24 , wherein the abnormal ...

Подробнее
Номер записи: 20
05-01-2017 дата публикации

Inhibitors of thioredoxin-interacting protein (TXNIP) for therapy

Номер: US20170002352A1
Автор: Gülow Karsten, Krammer Peter, ZIOLA Sabine
Принадлежит:

Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (TXNIP) or (b) the expression of the gene encoding TXNIP for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan. 19-. (canceled)10. A method of improving female fertility in a subject comprising administering a compound capable of reducing or inhibiting: (a) a biological activity of thioredoxin-interacting protein (TXNIP) or (b) an expression of a gene encoding TXNIP , wherein said compound is:(i) an antisense oligonucleotide or a small hairpin RNA (shRNA) that reduces or inhibits the expression of the gene encoding TXNIP, or(ii) an antibody directed against TXNIP or a fragment thereof that reduces or inhibits the biological activity of TXNIP, or(iii) an inactive TXNIP or nucleic acid sequences encoding an inactive TXNIP.11. A method for identifying a compound that improves female fertility by reducing or inhibiting a biological activity of TXNIP or an expression of a gene encoding TXNIP , comprising the steps of:(a) incubating a candidate compound with a test system comprising TXNIP or the gene encoding TXNIP; and 'wherein an inhibition or loss of the biological activity of TXNIP is indicative that the candidate compound improves female fertility.', '(b) assaying the biological activity of TXNIP;'}12. The method of claim 11 , wherein the inhibition or loss of the biological activity of TXNIP is determined by comparison to a test system without said candidate compound. This application is a Continuation of U.S. patent application Ser. No. 14/364,250, filed Jun. 10 2014, which is a U.S. National Phase Application under 35 U.S.C. §371 of International Patent Application No. PCT/EP2013/001143, filed Apr. 17, 2013, and claims the priority of European Patent Application No. 12002914.5, filed Apr. 25, 2012, all of which are incorporated ...

Подробнее
Номер записи: 21
03-01-2019 дата публикации

Monoclonal anti-tk1 antibodies

Номер: US20190002587A1
Автор: Staffan Eriksson
Принадлежит: AROCELL AB

The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.

Подробнее
Номер записи: 22
05-01-2017 дата публикации

In vitro assays for inhibition of microglial activation

Номер: US20170003280A1
Автор: Anke Meyer-Franke, Christopher Wilson, Katerina Akassoglou, Kean-Hooi Ang, Michelle Arkin
Принадлежит: J David Gladstone Institutes, UNIVERSITY OF CALIFORNIA

The present invention provides cell-based assays, including high throughput cell-based assays, for identification of candidate therapeutic agent with no known agents with the ability to inhibit microglial activation in vivo in response to different ligands.

Подробнее
Номер записи: 23
05-01-2017 дата публикации

Innate Immune Proteins As Biomarkers for CNS Injury

Номер: US20170003303A1
Автор: Adamczak Stephanie, Bullock M. Ross, De Rivero Vaccari Juan Pablo, Dietrich W. Dalton, Keane Robert W., Levi Allan, Wang Michael Y.
Принадлежит:

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the serverity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilition efforts, and monitor response to treatment for a patient with a central nervous system injury are also described. 132.-. (canceled)33. A method of treating a patient with a central nervous system (CNS) injury comprising administering a neuroprotective treatment to the patient with the central nervous system injury , wherein the patient comprises an elevated level of at least one inflammasome protein.34. The method of claim 33 , wherein the elevated level of at least one inflammasome protein was measured in a biological sample obtained from the patient.35. The method of claim 33 , wherein the elevated level of at least one inflammasome protein is relative to a pre-determined reference value or range of reference values.36. The method of claim 35 , wherein the elevated level of at least one inflammasome protein relative to the pre-determined reference value or range of reference values is predictive of the patient having a Glasgow Outcome Scale (GOS) score of 1 to 3 upon follow-up assessment.37. The method of claim 33 , wherein the neuroprotective treatment is hypothermia claim 33 , methylprednisolone claim 33 , 17α-estradiol claim 33 , 17β-estradiol claim 33 , ginsenoside claim 33 , progesterone claim 33 , simvastatin claim 33 , deprenyl claim 33 , minocycline claim 33 , or resveratrol.38. The method of claim 33 , wherein the neuroprotective treatment is a molecule that binds an inflammasome protein or epitope thereof.39. The method of claim 38 , wherein the molecule specifically binds to SEQ ID NO: 1 claim 38 , 2 claim 38 , 3 or ...

Подробнее
Номер записи: 24
05-01-2017 дата публикации

Method for detecting circulating tumour cells (ctcs)

Номер: US20170003306A1
Автор: Aigars PIRUSKA, Fabio DEL BEN, Giacinto SCOLES, Matteo TURETTA, Wilhelm Huck
Принадлежит: Stichting Katholieke Universiteit, STITCHING KATHOLIEKE UNIVERSITEIT, UNIVERSITÀ DEGLI STUDI DI UDINE

The present invention relates to a method for detecting circulating tumour cells (CTCs) in body fluids, preferably in blood and lymph. In particular, the method for detecting circulating tumour cells in a body fluid comprises a step of detecting a change in pH and/or in a concentration of at least one molecule selected from lactic acid, lactate ions and protons within an isolated volume of said body fluid in which a cell has been encapsulated.

Подробнее
Номер записи: 25
07-01-2016 дата публикации

USE OF PKC-ZETA AS A BREAST CANCER TUMORIGENIC BIOMARKER AS WELL AS A TARGET FOR TREATMENT OF BREAST CANCER

Номер: US20160003825A1
Автор: Acevedo-Duncan Mildred Enid, Hill Diondra D.
Принадлежит:

The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer. 1. A method for detecting PKC-zeta in a human breast tumor sample , wherein the method comprises:measuring the expression level of PKC-zeta in the breast tumor sample.2. The method of claim 1 , further comprising quantifying the expression level of the PKC-zeta protein.3. The method of claim 1 , wherein the expression level is determined by contacting the PKC-zeta protein with an antibody that specifically recognizes PKC-zeta in an immunoassay selected from radioimmunoassay claim 1 , western blot assay claim 1 , immunofluorescent assay claim 1 , enzyme immunoassay claim 1 , immunoprecipitation claim 1 , chemiluminescent assay claim 1 , immunohistochemical assay claim 1 , dot blot assay claim 1 , and slot blot assay. This application is a continuation of U.S. application Ser. No. 13/309,018, filed Dec. 1, 2011, which claims the benefit of U.S. Provisional Application Ser. No. 61/418,585, filed Dec. 1, 2010, the disclosures of each of which are incorporated herein by reference in their entirety.The present invention provides assays for prediction and detection of breast cancer tumorigenesis, as well as methods for treatment of breast cancer.Breast cancer is the most common female malignancy and the leading cause of cancer-related death among women. The 2011 cancer statistics estimated that 230,000 new cases of invasive breast cancer will be diagnosed that year and would result in 40,000 new deaths. In North America, breast cancer accounts for about 27% of all female cancers and 15%-20% of all female cancer mortalities. Also, approximately 1,700 men will be diagnosed with breast cancer and 450 will die each year. Despite significant educational efforts, improved diagnostic techniques, and rigorous therapies, breast cancer ...

Подробнее
Номер записи: 26
07-01-2016 дата публикации

USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS

Номер: US20160003855A1
Автор: Bowen Benjamin P., LOUIE Katherine B., NORTHEN Trent R.
Принадлежит:

Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. 1. A method for identifying one or more diseased cells in a subject , comprising:(a) providing a biological sample derived from a subject;(b) analyzing the biological sample by mass spectrometry; and(c) determining the abundance of one or more lipids in the biological sample, wherein an altered abundance of the one or more lipids in the biological sample, as compared to a reference level, indicates a presence of one or more diseased cells in the subject from which the biological sample is derived.2. The method of claim 1 , wherein the reference level is established using a reference sample from a healthy subject.3. (canceled)4. (canceled)5. The method of claim 1 , wherein the biological sample comprises a tissue sample claim 1 , a bodily fluid claim 1 , a cell culture or extracts thereof claim 1 , or a combination thereof.6. (canceled)7. (canceled)8. The method of claim 1 , wherein the biological sample comprises one or more lipid-containing microparticles.9. The method of claim 8 , wherein the one or more lipid-containing microparticles are exosomes claim 8 , cell membrane fragments claim 8 , cellular and intracellular organelle fragments claim 8 , lipid bilayers claim 8 , or a combination thereof.10. (canceled)11. (canceled)12. The method of claim 8 , wherein analyzing the biological sample by mass spectrometry comprises isolating the one or more lipid-containing microparticles from the biological sample and analyzing the lipid-containing microparticles by mass spectrometry.13. The method of claim 12 , wherein the isolating step comprises isolating the one or more lipid-containing microparticles from the biological sample by filtration claim 12 , centrifugation claim 12 , microfluidics claim 12 , antibody affinity capture claim 12 , or a ...

Подробнее
Номер записи: 27
04-01-2018 дата публикации

Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients

Номер: US20180003721A1
Автор: Krolewski Andrzej S., Niewczas Monika A.
Принадлежит: Joslin Diabetes Center

The present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease. 1. A method of predicting risk of developing renal disease in a patient who has diabetes , comprising:a) determining the levels of at least three metabolites selected from the group consisting of pseudouridine, C-glycosyltryptophan, myoinositol, threitol, p-cresol sulfate, 2-hydroxyisovalerate, 2-hydroxyisocaproate, glutaryl carnitine, N2, N2-dimethylguanosine, phenylacetylglutamine, arabitol, gulono-1,4-lactone, erythritol, erythronate, N4-acetylcytidine, urate, 2-hydroxyisocaproate, 2-oxoisoleucine, and 2-oxoisocaproate in a plasma or serum sample taken from the patient;b) comparing the levels of the metabolites in the sample from the patient to control levels of the metabolites; andc) predicting that the patient is at risk for developing renal disease when the levels of the metabolites in the sample from the patient are significantly higher than the control levels of the metabolites.2. The method of claim 1 , wherein the patient has type 2 diabetes.3. The method of claim 1 , wherein the patient has type 1 diabetes.4. The method of claim 1 , wherein the patient has normal renal function.5. The method of claim 1 , wherein the patient does not have symptoms of renal disease.6. The method of claim 1 , wherein the renal disease is diabetic nephropathy.7. The method of claim 1 , wherein the renal disease is end-stage renal disease (ESRD).8. The method of claim 1 , wherein the sample taken from the patient is a plasma sample.9. The method of claim 1 , wherein the levels of the metabolites are determined using mass spectrometry.10. A method of identifying a patient who has diabetes as being in need ...

Подробнее
Номер записи: 28
02-01-2020 дата публикации

NANOPOROUS BIOELECTROCHEMICAL SENSORS FOR MEASURING REDOX POTENTIAL IN BIOLOGICAL SAMPLES

Номер: US20200003754A1
Автор: Collinson Maryanne M., Daniels Rodney C., Ward Kevin R.
Принадлежит:

A bioelectrochemical sensor utilizing a nanoporous gold electrode. The bioelectrochemical sensor is suitable for measuring redox in biologic media while having increased resistance to biofouling as compared to conventional electrodes such as planar gold electrodes, due to greater exposed surface area of the three-dimensional ligature structure defining the nanopores. The nanopores have a pore size of 5-100 nm, preferably with an average pore size of less than 50 nm, and more preferably with an average pore size of less than 20 nm. 1. A bioelectrochemical sensor , comprising: a plurality of gold coated strips;', 'an etched gold leaf disposed over a surface of the plurality of gold coated strips;', 'a strip of TEFLON tape disposed over the etched gold leaf, the TEFLON tape having a hole therethrough positioned over the etched gold leaf; and, 'a first electrode including a nanoporous precious metal, the nanoporous precious metal of the first electrode being nanoporous gold, the first electrode including'}a reference electrode.2. (canceled)3. The bioelectrochemical sensor of claim 1 , the pores of the nanoporous precious metal of the first electrode having a pore size of 100 nm or less.4. The bioelectrochemical sensor of claim 3 , the nanoporous precious metal of the first electrode having an average pore size of less than 50 nm.5. The bioelectrochemical sensor of claim 3 , the nanoporous precious metal of the first electrode having an average pore size of less than 20 nm.6. The bioelectrochemical sensor of claim 1 , further comprising a counter electrode.7. The bioelectrochemical sensor of claim 1 , the reference electrode being a silver/silver chloride electrode.8. The bioelectrochemical sensor of claim 6 , the counter electrode being platinum.9. The bioelectrochemical sensor of claim 1 , in combination with a block having a microfluidic channel therein claim 1 , the microfluidic channel including a portion aligned with an exposed nanoporous region of the first ...

Подробнее
Номер записи: 29
02-01-2020 дата публикации

ISOTYPING IMMUNOGLOBULINS USING ACCURATE MOLECULAR MASS

Номер: US20200003784A1
Автор: Barnidge David R., Dasari Surendra, Mills John R., Murray David L.
Принадлежит: Mayo Foundation for Medical Education and Research

This document relates to methods for detecting and quantifying heavy and light chains of immunoglobulin using mass spectrometry techniques. 1. A method for detecting immunoglobulin heavy chains in a sample , the method comprising:a) providing a biological sample comprising immunoglobulins, paired immunoglobulin heavy and light chains, or mixtures thereof;b) immunopurifying the sample, wherein the immunopurifying comprises using an antibody selected from the group consisting of an anti-human IgG antibody, an anti-human IgA antibody, an anti-human IgM antibody, an anti-human IgD antibody, an anti-human IgE antibody, and combinations thereof;c) subjecting the immunopurified sample to a decoupling step wherein immunoglobulin light chains are decoupled from immunoglobulin heavy chains; andd) subjecting the decoupled sample to a mass spectrometry technique to obtain a mass spectrum of the sample, said mass spectrum comprising one or more peaks corresponding to one or more intact immunoglobulin heavy chains in the sample; wherein said one or more peaks quantify the amount of the one or more intact immunoglobulin heavy chains in the sample.2. The method of claim 1 , wherein the antibody is a non-human antibody.3. The method of claim 2 , wherein the non-human antibody is at least one of a camelid antibody claim 2 , a cartilaginous fish antibody claim 2 , llama claim 2 , sheep claim 2 , goat claim 2 , or a mouse antibody.4. The method of claim 3 , wherein the antibody is a single domain antibody fragment (SDAF).5. The method of claim 4 , wherein the SDAF is derived from a camelid antibody claim 4 , a cartilaginous fish antibody claim 4 , llama claim 4 , a mouse antibody claim 4 , sheep claim 4 , goat claim 4 , or a human antibody.6. The method of claim 5 , wherein the SDAF is selected such that the mass spectrum generated in step c) for the single domain antibody fragment does not overlap with the mass spectrum generated in step c) for the immunoglobulin light chain or ...

Подробнее
Номер записи: 30
02-01-2020 дата публикации

COMPOSITIONS AND METHODS FOR DETECTING AND/OR TREATING INFLAMMATION

Номер: US20200003791A1
Автор: Azroyan Anie, Breton Sylvie, Brown Dennis, Cortez-Retamozo Virna F., Pittet Mikael
Принадлежит: The General Hospital Corporation

The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor. 1. A method of treating renal inflammation comprising providing a composition comprising a P2Y14 inhibitor in a therapeutically effective amount to treat or prevent renal inflammation.2. The method of claim 1 , wherein the P2Y14 inhibitor is 4-((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (PPTN).3. The method of claim 1 , wherein the composition is suitable for delivery in an organ-specific delivery device.4. The method of claim 3 , wherein the delivery device is a renal catheter.5. The method of claim 1 , wherein the composition is suitable for delivery into renal circulation.6. The method of claim 1 , wherein the renal inflammation is associated with a condition selected from the group consisting of acute kidney injury claim 1 , chronic renal failure claim 1 , glomerulonephritis claim 1 , heterologous nephrotoxic nephritis claim 1 , an immune-related disease claim 1 , nephropathy claim 1 , pyelonephritis claim 1 , and sclerosis of the glomerulus.7. The method of claim 6 , wherein the renal inflammation is associated with acute kidney injury.8. The method of claim 1 , wherein the renal inflammation is early stage.9. A method of treating acute kidney injury comprising providing a composition comprising a P2Y14 inhibitor in a therapeutically effective amount to treat or prevent acute kidney injury.10. The method of claim 9 , wherein the P2Y14 inhibitor is PPTN.11. The method of claim 9 , wherein the composition is suitable for delivery in an organ-specific delivery device.12. The method of claim 11 , wherein the delivery device is a renal catheter.13. The method of claim 9 , wherein the composition is suitable for delivery ...

Подробнее
Номер записи: 31
02-01-2020 дата публикации

DIAGNOSTIC METHOD

Номер: US20200003792A1
Автор: LOMONOSOV Mikhail, ROSSMAN Maxim, SOLOVYEV Dmitry, ZAICHIK Sofia, ZAYCHIK Vladimir
Принадлежит: Cambridge Oncometrix Limited

The disclosure is directed to a method of diagnosing a prostate condition in a subject by determining, in a sample obtained from a subject, levels of a plurality of constituents selected from the group consisting of Ca, K, Mg, Zn, Ag, AI, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, Hg, Ho, La, Li, Mn, Na, Nd, Ni, P, Pb, Pr, Rb, S, Sb, Sc, Se, Si, Sm, Sr, Tb, Th, Tl, U, Y, and Zr. A combination of the levels of the plurality of constituents in the sample is compared with a combination of control levels of the same plurality of constituents. A difference between the combinations is indicative of the prostate condition. 1. A method of diagnosing a prostate condition in a subject , comprising:determining, in a sample obtained from a subject, levels of a plurality of constituents selected from the group consisting of Ca, K, Mg, Zn, Ag, Al, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, Hg, Ho, La, Li, Mn, Na, Nd, Ni, P, Pb, Pr, Rb, S, Sb, Sc, Se, Si, Sm, Sr, Tb, Th, Tl, U, Y, and Zr; andcomparing a combination of the levels of the plurality of constituents in the sample with a combination of control levels of the same plurality of constituents, in which a difference between the combinations is indicative of the prostate condition.218.-. (canceled)19. A method according to claim 1 , wherein the prostate condition is prostate cancer.20. A method according to claim 19 , wherein the sample obtained from the subject comprises seminal fluid or expressed prostatic secretion.21. A method according to claim 19 , comprising determining levels of least five of the constituents.22. A method according to claim 19 , comprising determining levels of at least six of the constituents.23. A method of diagnosing a prostate condition in a subject claim 19 , comprising:determining, in sample obtained from a subject, a level of at least one constituent selected from the group consisting of Ca, K, Mg, Ag, Al, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, ...

Подробнее
Номер записи: 32
07-01-2021 дата публикации

A Radiomics-Based Imaging Tool to Monitor Tumor-Lymphocyte Infiltration and Outcome in Cancer Patients Treated by Anti-PD-1/PD-L1

Номер: US20210003555A1
Автор: Deutsch Eric, FERTE CHARLES, LIMKIN Elaine Johanna, SUN Roger
Принадлежит: INSTITUT GUSTAVE-ROUSSY

The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and/or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1/PD-L1 monotherapy. 114.-. (canceled)15. A method for evaluating the quantity and /or spatial density of CD8+ T cells infiltrating a solid tumor , said method comprising the use of a radiomics-based signature.16. The method of claim 15 , wherein said signature is generated using non-invasive imagining technologies.17. The method of claim 15 , wherein said signature is generated using scanners claim 15 , magnetic resonance imaging (MRI) claim 15 , or PET (Positron Emission Tomography).18. The method of claim 15 , wherein said signature is generated using a computed tomography (CT) scan.19. The method of claim 15 , wherein said radiomic-based signature comprises at least six radiomic variables.20. The method of claim 15 , wherein said radiomic-based signature contains:at least one conventional variable,at least one Gray-level Run Length Matrix (GLRLM) variable,at least one acquisition marker, and/orat least one localization marker.21. The method of claim 20 , wherein said conventional variable is minValue.22. The method of claim 20 , wherein said acquisition marker is kilovoltage peak (kVp).23. The method of claim 20 , wherein said localization marker is VOI.24. The method of claim 20 , wherein said radiomic-based signature comprises:minValue of the tumor as conventional variable;four Gray-level Run Length Matrix (GLRLM) variables consisting of: GLRLM_SRHGE of the tumor, GLRLM_SRLGE of the ring, GLRLM_LGRE of the ring, and GLRLM_LRLGE of the ring;acquisition marker kVp; andtwo localization markers ...

Подробнее
Номер записи: 33
07-01-2021 дата публикации

Method for Improving Quality of Therapeutic Cell Through Real-Time Glutathione Measurement

Номер: US20210003582A1
Автор: KANG Heun Soo, Kang Hye Won, KIM Hye Mi, KIM Myung Jin, KIM Yong Hwan, Shin Ji Woong, Song Ji Eun, Yang Gwang Mo
Принадлежит:

The present invention relates to a method of improving the quality of therapeutic cells by real-time glutathione monitoring. 1. A method of improving the quality of cells , comprising:isolating desired cells;measuring a glutathione level in the isolated cells;determining cell quality according to the glutathione level; andadding a material capable of improving a glutathione evaluation parameter into the isolated cells.2. The method according to claim 1 , wherein the determination of cell quality according to the glutathione level is performed according to one or more selected from the group consisting of the following evaluation parameters:i) glutathione mean or median level (GM) of cells;ii) glutathione heterogeneity (GH) of cells;iii) glutathione regeneration capacity (GRC) of cells; andiv) oxidative stress resistance capacity (ORC),{'b': '510', 'where GM is calculated as the mean value or median value of a cellular FreSH-tracer ratio (FR) or F,'}{'b': '510', 'GH is calculated as the coefficient of variation or the robust coefficient of variation of cellular FR or F,'}{'b': '510', 'GRC is a value obtained by real-time monitoring of FR or F after cells are treated with an oxidizing agent, and is calculated by dividing a value obtained by subtracting a second area under the curve (AUC) of a group treated with a second oxidizing agent from a first AUC of a group treated with a first oxidizing agent by a value obtained by subtracting the second AUC of the group treated with the second oxidizing agent from a third AUC of a naive control and multiplying the resulting value by 100, and'}ORC is a value of cell counts with the variation in GSH expression, obtained by comparing the GSH levels quantified after living cells are treated with a first oxidizing agent with the GSH levels quantified in control cells which are not treated with an oxidizing agent or in control cells which have not been treated with an oxidizing agent yet.3. The method according to claim 1 , wherein ...

Подробнее
Номер записи: 34
01-01-2015 дата публикации

ADENOVIRAL TUMOR DIAGNOSTICS

Номер: US20150005397A1
Автор: "OShea Clodagh", Powers Colin
Принадлежит:

Compositions and methods for detecting a cancer in a subject using a recombinant reporter adenovirus are described. In particular, recombinant adenovirus is used to diagnose a cancer in a patient and further used for screening compounds effective in treating the cancer in said patient. 1. A recombinant reporter adenovirus , comprising a cancer cell reporter module and a cancer cell binding module , wherein said cancer cell reporter module comprises a cancer responsive promoter operably linked to a reporter gene.2. The recombinant reporter adenovirus of claim 1 , further comprising an immune evasion module.3. The recombinant reporter adenovirus of claim 1 , wherein said reporter gene is a fluorescent reporter gene.4. The recombinant reporter adenovirus of claim 1 , wherein said cancer cell reporter module is a first cancer cell reporter module and said recombinant reporter adenovirus further comprises a second cancer cell reporter module and a third cancer cell reporter module.5. The recombinant reporter adenovirus of claim 4 , wherein said first cancer cell reporter module is capable of expressing a first reporter gene phenotype claim 4 , said second cancer cell reporter module is capable of expressing a second reporter gene phenotype claim 4 , and said third cancer cell reporter module is capable of expressing a third reporter gene phenotype.6. The recombinant reporter adenovirus of claim 5 , wherein said first reporter gene phenotype claim 5 , said second reporter gene phenotype claim 5 , and said third reporter gene phenotype are each detectably different.7. The recombinant reporter adenovirus of claim 5 , wherein said first reporter gene phenotype is indicative of a first cancer claim 5 , said second reporter gene phenotype is indicative of a second cancer claim 5 , and said third reporter gene phenotype is indicative of a third cancer.8. The recombinant adenovirus of claim 7 , wherein said first cancer claim 7 , said second cancer and said third cancer are ...

Подробнее
Номер записи: 35
03-01-2019 дата публикации

METHODS OF SCREENING

Номер: US20190004058A1
Автор: HARDWICK Bryn Shaun, MCKENZIE Grahame James
Принадлежит:

The invention provides a method of identifying a peptide interaction site on a target protein wherein the target protein modulates the phenotype of a mammalian cell, using mammalian encoded peptides (SEPs) such as short open reading frame (sORF) encoded peptides. The invention further provides a method for the identification of new therapeutic targets and protein interaction sites for use in drug discovery. 1. A method of identifying a target protein that modulates a phenotype of a mammalian cell , said method comprisingexposing a population of in vitro cultured mammalian cells capable of displaying said phenotype to a library of short expressed peptides (SEPs);identifying in said cell population an alteration in said phenotype following said exposure;selecting cells undergoing a phenotypic change and identifying a SEP of the library of SEPs that alters the phenotype of the cells; andproviding said SEP and identifying a cellular protein that binds to said SEP, said cellular protein being a target protein that modulates the phenotype of the mammalian cell.2. A method according to wherein the library of SEPs comprises human SEPs.3. A method according to claim 1 , wherein the library of SEPs includes peptide products of short open reading frames (ORFs).4. A method according to claim 1 , wherein the SEP is a peptide of 6-130 amino acids or a nucleic acid sequence encoding for said peptide.5. A method according to claim 1 , wherein the SEP is a peptide of 6 to 100 amino acids or a nucleic acid sequence encoding for said peptide.6. A method according to claim 1 , wherein the cellular protein and the SEP are used in an assay to identify ligands that bind to said cellular protein and disrupt SEP binding.7. A method of identifying a compound which binds to a target protein and displaces or blocks binding of a short expressed peptide (SEP) claim 1 , wherein the compound modulates a phenotype of a mammalian cell claim 1 , said method comprising the steps:i. exposing a ...

Подробнее
Номер записи: 36
07-01-2021 дата публикации

Method and system for personalized, molecular based health management and digital consultation and treatment

Номер: US20210005327A1
Автор: Ana Gabriela Marcu, Mohammad Ashraful Anwar, Nitya Bourdel, Robert Allan Fraser
Принадлежит: Molecular You Corp

The present disclosure relates to personalized health, specifically molecular based health management and digital consultation. In particular, the present disclosure is directed to methods and systems for assessing the health status of an individual based on correlations between multi-omics measures (e.g., genomics, metabolomics, exposomics and proteomics) and diseases or health risks as disclosed in published research data. The disclosure also relates to methods and systems for customized counseling to individuals regarding health status and actionable measures to improve their health status.

Подробнее
Номер записи: 37
08-01-2015 дата публикации

DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR CANCER

Номер: US20150008314A1
Автор: LIU Jinbo, Sessler Daniel I.
Принадлежит: THE CLEVELAND CLINIC FOUNDATION

A method for detecting cancer from a biological sample previously withdrawn from the subject, in a subject includes determining in vitro the level of at least one biomarker in the biological sample. The at least one biomarker includes a phospholipid or a free fatty acid. A level of the at least one biomarker that is 2-fold greater than the level of at least one biomarker in a control is indicative of cancer in the subject. 1. A method for detecting cancer in a subject from a biological sample previously withdrawn from the subject , the method comprising determining in vitro the level of at least one biomarker in the biological sample , the at least one biomarker including a phospholipid or a free fatty acid , wherein a level of the at least one biomarker that is at least about 2-fold greater than the level of at least one biomarker in a control is indicative of cancer in the subject.2. The method of claim 1 , wherein the biological sample is selected from the group consisting of whole blood claim 1 , plasma and serum.3. The method of claim 2 , wherein the biological sample is about 0.5 ml of blood.4. The method of claim 1 , wherein the level of the at least one biomarker in the subject is determined using mass spectroscopy.5. The method of claim 4 , wherein the level of the at least one biomarker in the subject is determined using electrospray ionization tandem mass spectroscopy.6. The method of claim 1 , wherein the free fatty acid is at least one of linoleic acid (LA) or arachidonic acid (AA).7. The method of claim 1 , wherein the free fatty acid is at least one of a hydroxyeicosatetraenoic acid (HETE) or a hydroxyoctadecadienoic acid (HODS).8. The method of claim 7 , wherein the HETE is selected from the group consisting of 15-HETE claim 7 , 12-HETE claim 7 , 11-HETE and 5-HETE.9. The method of claim 1 , wherein the phospholipid is a lysophosphatylcholine (LPC) or HODE-PC.10. The method of claim 9 , wherein the LPC is LPC-C16.11. The method of claim 7 , wherein ...

Подробнее
Номер записи: 38
20-01-2022 дата публикации

INFLAMMATION-ENABLING POLYPEPTIDES AND USES THEREOF

Номер: US20220017960A1
Автор: GROS Philippe
Принадлежит:

This present technology relates to the use of inflammation-enabling polypeptides (or their coding sequences) to screen for agents useful for the prevention, treatment and/or alleviations of symptoms associated with an inflammatory disorder, to identify individuals susceptible of developing an exacerbated inflammatory response as well as to determine if a therapeutic regimen is capable of preventing, treating or alleviating the symptoms associated to an inflammatory disorder in an individual. The present technology also provides methods for preventing, treating and/or alleviating the symptoms associated to an inflammatory condition based on the inhibition of expression or activity of the inflammation-enabling targets. 1. A method for assessing the ability of an agent to prevent , treat and/or alleviate the symptoms associated with an inflammatory condition in an individual , said method comprising:a) combining the agent with an inflammatory enabling polypeptide selected from the group consisting of a USP15 polypeptide and a TRIM25 polypeptide;b) measuring a biological activity of the inflammatory enabling polypeptide of step (a) to obtain a test level;c) comparing the test level to a control level, wherein the control level is associated with the biological activity of the inflammatory enabling polypeptide observed during the onset or maintenance of the inflammatory condition; andd) characterizing the agent as (i) useful for the prevention, treatment and/or alleviation of the symptoms associated with the inflammatory condition when the at least one biological activity associated with the test level is lower than the biological activity associated with the control level or (ii) lacking utility for the prevention, treatment and/or alleviation of the symptoms associated with the inflammatory condition when the at least one biological activity associated with the test level is equal to or higher than the biological activity associated with the control level.2. The method ...

Подробнее
Номер записи: 39
08-01-2015 дата публикации

SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID

Номер: US20150011412A1
Автор: Birkmeyer Richard C., Cameron Alexander, Chung Eun Kyung, Deirmengian Carl, Kardos Keith, Kilmartin Patrick, Schiller Kevin
Принадлежит:

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. 1. (canceled)2. A system for diagnosing joint infection in a subject , wherein the system comprises:a) a first region comprising a first detection reagent that detects the presence of the biomarker for joint infection in synovial fluid, wherein the first detector reagent specifically binds the biomarker,b) a second region comprising an internal control detector reagent comprising an immunoglobulin;wherein detection of the biomarker diagnoses joint infection in the subject with at least 90% accuracy.3. (canceled)4. The system of claim 2 , wherein the biomarker is selected from the group consisting of defensin claim 2 , HNP1-3 claim 2 , ELA-2 claim 2 , BPI claim 2 , NGAL claim 2 , Resistin claim 2 , Thrombospondin claim 2 , Lactoferrin claim 2 , IL-1β claim 2 , IL-8 claim 2 , CRP claim 2 , TNFα claim 2 , IL-6 claim 2 , HNE claim 2 , a2M claim 2 , VEGF claim 2 , FGF2 claim 2 , SKALP claim 2 , IP-10 claim 2 , LMP claim 2 , Orsomucoid claim 2 , and any combination thereof.5. (canceled)6. The system of claim 2 , wherein the system has a sensitivity and specificity of at least 90% for joint infection.7. The system of claim 2 , wherein the joint is selected from the group consisting of a native joint and a replacement joint.8. (canceled)9. A method of diagnosing joint infection in a subject comprising detecting the presence of a biomarker in synovial fluid obtained from a joint in the subject claim 2 , the method comprising applying synovial fluid obtained from a joint in the subject to a system claim 2 , a) a first region comprising a ...

Подробнее
Номер записи: 40
08-01-2015 дата публикации

ELECTROCHEMICAL DETECTION OF PROTEASES USING AC VOLTAMMETRY ON NANOELECTRODE ARRAYS

Номер: US20150011421A1
Автор: Hua Duy, LI JUN, Prior Allan, Swisher Luxi, Syed Lateef Uddin
Принадлежит:

An electrochemical method for measuring the activity of enzymes using nanoelectrode arrays fabricated with vertically aligned carbon nanofibers. Short peptide substrates specific to disease-related enzymes are covalently attached to the exposed nanofiber tips. A redox moiety, such as ferrocene, can be linked at the distal end of the nanofibers. Contact of the arrays with a biological sample containing one or more target enzymes results in cleavage of the peptides and changes the redox signal of the redox moiety indicating the presence of the target enzymes. 1. A nanoelectrode array comprising a substrate having a plurality of carbon nanofibers extending vertically therefrom , said array being capable of detecting the presence of one or more enzymes present within a biological sample.2. The array according to claim 1 , wherein said nanofibers comprise a proximal end that is attached to said substrate and a distal end that is spaced from said substrate.3. The array according to claim 2 , wherein said nanofibers are encapsulated claim 2 , except for at least one of said distal ends claim 2 , within a matrix of an insulative material.4. The array according to claim 3 , wherein said insulative material comprises silicon dioxide.5. The array according to claim 2 , wherein said distal end of at least one of said nanofibers comprises a peptide or peptide residue covalently attached thereto.6. The array according to claim 5 , wherein said peptide or peptide residue is capable of being cleaved by a protease enzyme that is expressed by a cancer-causing cell.7. The array according to claim 6 , wherein said peptide is a tetrapeptide selected from the group consisting of Ala-Ala-Asn-Leu (SEQ ID NO:1) claim 6 , Leu-Arg-Phe-Gly (SEQ ID NO:2) claim 6 , and Pro-Leu-Ser-Leu (SEQ ID NO:3).8. The array according to claim 5 , wherein said peptide or peptide residue is a ferrocenyl peptide or peptide residue.9. The array according to claim 5 , wherein said peptide or peptide residue is ...

Подробнее
Номер записи: 41
11-01-2018 дата публикации

ANTIBODIES AGAINST NOTCH 3

Номер: US20180009889A1
Автор: DEPLAZES-LAUBER Joelle, FRYER Christy, HU Tiacen, Jenkins David, Petropoulos Konstantin, THIEL Philippe
Принадлежит: NOVARTIS AG

The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof. 19-. (canceled)10. The isolated antibody or fragment thereof of claim 45 , wherein the antibody or fragment thereof stabilizes the Notch 3 receptor LNR region in the autoinhibited state.11. The isolated antibody or fragment thereof of claim 45 , wherein the Notch 3 receptor is a mutant Notch 3 receptor claim 45 , wherein the LNR region or the HD domain has at least one amino acid residue mutation.1227-. (canceled)28. The isolated antibody or fragment thereof of claim 45 , wherein the antibody is selected from the group consisting of a monoclonal antibody claim 45 , a polyclonal antibody claim 45 , a chimeric antibody claim 45 , a humanized antibody claim 45 , and a synthetic antibody.29. The isolated antibody or fragment thereof of claim 45 , wherein the antibody or fragment thereof inhibits Notch 3 signaling as assessed by an assay selected from the group consisting of a Notch 3 ligand-driven reporter gene assay claim 45 , FACS assay claim 45 , Notch 3 target gene mRNA quantitation claim 45 , in vitro proliferation of TALL-1 cells claim 45 , and by detecting gamma secretase cleaved form of Notch 3 intracellular domain (ICD).3032-. (canceled)33. An isolated antibody or fragment thereof of claim 45 , comprising a variable heavy chain sequence and a variable light chain sequence selected from the group consisting of:a variable heavy chain having SEQ ID NO: 9 and a variable light chain sequence having SEQ ID NO: 19;variable heavy chain sequence having SEQ ID NO: 29 and a variable light chain sequence having SEQ ID NO: 39;a variable heavy chain sequence having SEQ ID NO: 49 and a variable light chain sequence having SEQ ID NO: 59;a variable heavy chain sequence having SEQ ID NO: 69 and a variable light chain sequence having SEQ ID NO: 79;a variable heavy chain sequence ...

Подробнее
Номер записи: 42
14-01-2021 дата публикации

HUMANIZED TAU ANTIBODIES IN ALZHEIMER'S DISEASE

Номер: US20210009666A1
Автор: KONTSEKOVÀ Eva, Kovacech Branislav, Novak Michal, Skrabana Rostislav
Принадлежит:

The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau. 1179-. (canceled)180. An anti-tau antibody , or a tau-binding fragment thereof , wherein said antibody or binding fragment comprises:a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NOs. 1, 2, and 3, respectively, and one or more framework regions from SEQ ID NO. 13 or one or more framework regions which has been substituted relative to a framework from SEQ ID NO. 13 at one or more positions selected from 9, 21, 27, 28, 30, 38, 48, 67, 68, 70, and 95;a light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NOs. 4, 5, and 6, respectively, and one or more framework regions from SEQ ID NO. 26 or one or more framework regions which has been substituted relative to a framework from SEQ ID NO. 26 at position 5; andheavy chain and light chain constant regions each from a human immunoglobulin;wherein position numbering is according to Kabat.181. The antibody or binding fragment of claim 180 , wherein the heavy chain variable region framework position 9 is P claim 180 , the heavy chain variable region framework position 21 is P claim 180 , the heavy chain variable region framework position 27 is Y claim 180 , the heavy chain variable region framework position 28 is I claim 180 , the heavy chain variable region framework position 30 is T claim 180 , the heavy chain variable region framework position 38 is K claim 180 , the heavy chain variable region framework position 48 is I claim 180 , the heavy chain variable region framework position 67 is K claim 180 , the heavy chain variable region framework position 68 is A claim 180 , the heavy chain variable region framework position 70 is L claim 180 , and/or the heavy ...

Подробнее
Номер записи: 43
10-01-2019 дата публикации

ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR PREVENTION OR REDUCTION OF ORGAN DYSFUNCTION OR ORGAN FAILURE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION

Номер: US20190010226A1
Автор: Bergmann Andreas
Принадлежит: ADRENOMED AG

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure. 126.-. (canceled)28. The antibody or fragment thereof of claim 27 , wherein the C-terminal histidine residues of SEQ ID NOs 7-11 are not present.29. The antibody or fragment thereof of claim 27 , wherein (i) CDR1: amino acids 26-33 (SEQ ID NO: 1),', '(ii) CDR2: amino acids 51-58 (SEQ ID NO: 2), and', '(iii) CDR3: amino acids 97-107 (SEQ ID NO: 3), and, 'the invariant CDR sequences in the heavy chain variable regions are located within the heavy chain of SEQ ID NOs 7-11 at the following positions (i) CDR1: amino acids 27-37 (SEQ ID NO: 4),', '(ii) CDR2: amino acids 55-57 (SEQ ID NO: 5), and', '(iii) CDR3: amino acids 94-102 (SEQ ID NO: 6)., 'the invariant CDR sequences in the light chain variable regions are located within the light chain of SEQ ID NOs 12-14 at the following positions30. The antibody or fragment thereof of claim 28 , wherein (i) CDR1: amino acids 26-33 (SEQ ID NO: 1),', '(ii) CDR2: amino acids 51-58 (SEQ ID NO: 2), and', '(iii) CDR3: amino acids 97-107 (SEQ ID NO: 3), and, 'the invariant CDR sequences in the heavy chain variable regions are located within the heavy chain of SEQ ID NOs 7-11 at the following positions (i) CDR1: amino acids 27-37 (SEQ ID NO: 4),', '(ii) CDR2: amino acids 55-57 (SEQ ID NO: 5), and', '(iii) CDR3: amino acids 94-102 (SEQ ID NO: 6)., 'the invariant CDR sequences in the light chain ...

Подробнее
Номер записи: 44
14-01-2016 дата публикации

RESIN PARTICLES FOR FLUORESCENT LABELS

Номер: US20160011179A1
Автор: Takahashi Masaru, TAKANASHI Kensaku
Принадлежит:

An object of the present invention is to provide a fluorophore having excellent initial emission intensity and light resistance, which is not easily discolored and does not affect the evaluation of the number of bright spots even when it is slightly discolored. The resin particle for fluorescence labeling is characterized by comprising a fluorescent dye immobilized in a resin particle, the fluorescent dye satisfying both of the following conditions (1) and (2): (1) the fluorescent dye alone in an aqueous solution has a concentration-dependent peak emission intensity in a range of 30 to 80 μM; and (2) the emission intensity at a concentration of 100 μM is not less than 80% of the peak emission intensity. It is preferred that the Stoke's shift of the fluorescent dye in an aqueous solution is not less than 25 nm. The fluorescent dye may be subjected to a solubilization treatment (such as an acid treatment). It is preferred that the fluorescent dye be encapsulated in a resin particle comprising a thermosetting resin. 1. A resin particle for fluorescent labeling , comprising a fluorescent dye immobilized in a resin particle , said fluorescent dye satisfying both of the following conditions (1) and (2):(1) said fluorescent dye alone in an aqueous solution has a concentration-dependent peak emission intensity in a range of 30 to 80 μM; and(2) the emission intensity at a concentration of 100 μM is not less than 80% of said peak emission intensity.2. The resin particle for fluorescent labeling according to claim 1 , wherein the Stoke's shift of said fluorescent dye in an aqueous solution is not less than 25 nm.3. The resin particle for fluorescent labeling according to claim 1 , wherein said fluorescent dye has been subjected to a solubilization treatment.4. The resin particle for fluorescent labeling according to claim 1 , wherein said solubilization treatment is an acid treatment.5. The resin particle for fluorescent labeling according to claim 1 , wherein said fluorescent ...

Подробнее
Номер записи: 45
14-01-2016 дата публикации

Application of N-terminomics to NETosis in inflammation

Номер: US20160011209A1
Автор: HERMISTON Terry, JIN Ye, MURPHY John E
Принадлежит:

Provided herein are protein biomarkers for NETosis related diseases, including proteases. Also provided are substrate sequences of such proteases and uses thereof. 1. A method for identifying a subject having a NETosis-related inflammatory condition , wherein NETosis is Neutrophil cell death forming Extracellular Traps , comprising:(a) obtaining information on NET-associated protease content from a sample from the subject;(b) comparing the level of NET-associated protease content with that of a comparable sample from a healthy subject, and(c) identifying the subject as having a NETosis-related inflammatory condition when the NET-associated protease content of the sample is greater than that of the comparable sample from the healthy subject.2. The method of claim 1 , wherein the sample is a blood sample.3. The method of claim 1 , wherein the protease is selected from the group consisting of neutrophil elastase (NE) claim 1 , cathepsin G (CG) claim 1 , proteinase 3 (PR3) claim 1 , and neutrophil secreted protein 4 (NSP4).43. The method any one of - claims 1 , further comprising treating the NETosis-related inflammatory condition.5. The method of claim 4 , wherein the inflammatory condition is selected from the group consisting of infection claim 4 , systemic lupus erythematosus claim 4 , rheumatoid arthritis claim 4 , cystic fibrosis claim 4 , deep vein thrombosis claim 4 , pre-eclampsia claim 4 , periodontitis claim 4 , appendicitis claim 4 , tuberculosis claim 4 , and Crohn's disease.6. The method of claim 4 , wherein treating comprises administering to the subject a protease inhibitor.7. The method of claim 6 , wherein the protease inhibitor inhibits cleavage of peptide substrate comprising a sequence set forth in .8. The method of claim 4 , wherein treating comprises administering to the subject a steroid or non-steroidal anti-inflammatory drug.9. The method of claim 4 , wherein treating comprises administering to the subject an antibiotic.10. The method of claim ...

Подробнее
Номер записи: 46
14-01-2016 дата публикации

METHODS TO PREDICT AND PREVENT RESISTANCE TO TAXOID COMPOUNDS

Номер: US20160011211A1
Автор: Chatterjee Sabarni K., Zetter Bruce R.
Принадлежит:

Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. 3. The method of or , wherein the subject had been treated with the member of the taxoid family.4. The method of or , wherein the member of the taxoid family is paclitaxel or docetaxel.5. The method of or , wherein serial monitoring of the level of prohibitin is performed at least quarterly , at least bimonthly , at least biweekly , at least weekly , at least every three days or at least daily.6. The method of or , wherein the level of prohibitin is measured by measuring the level of prohibitin on the cell surface of cancer cells in the biological sample.7. The method of or , wherein the biological sample is selected from the group consisting of blood , tissue , serum , plasma , urine , stool , cerebrospinal fluid , nipple aspirates , tumor biopsy , and cell lysate.8. The method of claim 7 , wherein the biological sample is a cell lysate and the level of prohibitin is measured by measuring the level of prohibitin in the microsomal fraction of the biological sample.9. The method of claim 7 , wherein the biological sample is serum and the level of prohibitin is determined by measuring the level of prohibitin in the serum.10. The method of claim 7 , wherein the biological sample is blood and the level of prohibitin is determined by measuring the level of prohibitin in platelets of the blood sample.11. The method of or claim 7 , wherein the level of prohibitin protein is measured using an antibody-based binding moiety which specifically binds prohibitin.12. The method according to claim 11 , wherein the antibody-based binding moiety is labeled with a detectable label.13. The method according to claim 12 , wherein the label is selected ...

Подробнее
Номер записи: 47
09-01-2020 дата публикации

INHIBITION OF THE AGGREGATION OF TRANSTHYRETIN BY SPECIFIC BINDING OF PEPTIDES TO AGGREGATION-DRIVING SEGMENTS

Номер: US20200010507A1
Автор: Eisenberg David S., Gomez Lorena Saelices
Принадлежит: The Regents of the University of California

The invention disclosed herein relates to peptide inhibitors for transthyretin (TTR) aggregation and methods of inhibiting TTR aggregation, cytotoxicity, and/or TTR amyloidosis. Illustrative embodiments of the invention include a composition of matter comprising at least one peptide designed to inhibit the aggregation of TTR, with this peptide typically being coupled to a heterologous amino acid tag. A pharmaceutically acceptable carrier selected to be compatible with the inhibitory peptide may also be included. A method for blocking or inhibiting the aggregation of transthyretin TTR is also provided. The method comprises combining TTR with an effective amount of an inhibitory peptide or pharmaceutical composition, so that TTR aggregation and/or cytotoxicity is blocked or inhibited 1. A composition of matter comprising at least one inhibitory peptide that inhibits transthyretin (SEQ ID NO: 1) aggregation by binding to residues 22 to 48 (strands B and C) , residues 86 to 97 (strand F) , or residues 113 to 124 (strand H) of transthyretin; wherein:at least one of the amino acids in the inhibitory peptide comprises a non-naturally amino acid; and/orthe inhibitory peptide is coupled to a heterologous peptide tag.3. The composition of claim 2 , wherein the non-naturally occurring amino acid comprises at least one of:a D-amino acid; oran amino acid comprising a N-methyl group moiety.4. The composition of claim 2 , wherein the heterologous peptide tag comprises:an amino acid sequence that increases peptide solubility; and/oran amino acid sequence that facilitates monitoring of the peptide.5. The composition of claim 4 , wherein the heterologous peptide tag comprises:a plurality of arginine amino acids; ora plurality of histidine residues.6. The composition of claim 1 , wherein the inhibitory peptide is from 6 to 30 amino acids in length.7. The composition of claim 2 , wherein the composition comprises a plurality of inhibitory peptides.8. A composition of claim 2 , wherein ...

Подробнее
Номер записи: 48
11-01-2018 дата публикации

DIAGNOSIS OF RISK OF UROTHELIAL CANCER

Номер: US20180011115A1
Автор: Fitzgerald Peter, Lamont John, Reid Cherith N., Ruddock Mark W., Williamson Kate E.
Принадлежит:

The present invention related to a method for detecting a history of exposure to a chemical(s) comprising measuring the concentration of thrombomodulin in a sample isolated from a subject, and determining whether the concentration of thrombomodulin is altered compared to control reference levels. 1. A method for detecting a history of exposure to a chemical(s) comprising measuring the concentration of thrombomodulin in a sample isolated from a subject , and determining whether the concentration of thrombomodulin is altered compared to control reference levels.2. The method of claim 1 , wherein the sample is a baseline sample from the subject.3. The method of claim 1 , wherein exposure to a chemical(s) is indicated by increased thrombomodulin levels in the sample.4. The method of claim 1 , wherein the sample is urine and/or serum and/or plasma.5. The method of claim 1 , wherein the subject suffers or has suffered from hematuria.6. The method of claim 1 , wherein the subject has had or is suspected of having prior history of exposure to a chemical selected from the list comprising 1 claim 1 ,1-dichloroethane claim 1 , 2-mercaptobenzothiazole claim 1 , β-naphthylamine or 2-naphthylamine claim 1 , 4 claim 1 ,4′-Methylenebis (2-chloroaniline) MOCA claim 1 , 4-aminobiphenyl claim 1 , aromatic amines claim 1 , arsenic claim 1 , auramine claim 1 , benzidine claim 1 , xenylamine claim 1 , benzidine-derived dyes claim 1 , aniline and azo dyes claim 1 , benzo(a)pyrene claim 1 , chlordimeform/4-COT claim 1 , coal tars claim 1 , direct black 38 claim 1 , direct blue 6 claim 1 , direct brown 95 claim 1 , nitrobiphenyl claim 1 , o-toluidine claim 1 , PAHs claim 1 , tobacco smoke claim 1 , carbaryl claim 1 , chlorination byproducts claim 1 , chlornaphazine claim 1 , chlorophenols claim 1 , creosotes claim 1 , methylenedianiline claim 1 , propoxur claim 1 , solvent claim 1 , trihalomethanes claim 1 , antimony claim 1 , asbestos claim 1 , bifenthrin claim 1 , cacodylic acid claim 1 , ...

Подробнее
Номер записи: 49
14-01-2021 дата публикации

ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS

Номер: US20210011022A1
Автор: ADELAKUN Olufemi A., CHAKRABORTY Indrani, Chen Guodong, HAN Michelle Minhua, HENNING Karla A., Huang Haichun, Huang Richard Y., Korman Alan J., LEWIN Anne C., LI Huiming, Lonberg Nils, Selby Mark J., SRINIVASAN Mohan, Wang Changyu, Wang Xi-Tao, WONG Susan Chien-Szu
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy. 139-. (canceled)40. A chimeric antibody which binds to human glucocorticoid-induced tumor necrosis factor receptor (GITR) and comprises a heavy chain comprising a heavy chain constant region , and a light chain comprising a light chain constant region , wherein the heavy chain comprises heavy chain variable region CDR1 , CDR2 , and CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 5-7 , respectively , and the light chain comprises light chain variable region CDR1 , CDR2 , and CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 8-10 , respectively , wherein the heavy chain constant region is a non-human constant region.41. The antibody of claim 40 , wherein the non-human constant region comprises a mouse Fc region.42. The antibody of claim 41 , wherein the mouse Fc region is a mouse IgG2a Fc region.43. The antibody of claim 40 , wherein the antibody comprises the heavy and light chain sequences set forth in SEQ ID NOs: 15 and 16 claim 40 , respectively.44. The antibody of claim 40 , wherein the antibody comprises a detectable moiety.45. The antibody of claim 44 , wherein the detectable moiety is selected from the group consisting of: a radiolabel claim 44 , a fluorescent label claim 44 , an enzymatic label claim 44 , biotin claim 44 , a chromophore claim 44 , and an ECL label.46. The antibody of claim 45 , wherein the detectable moiety is a fluorescent label claim 45 , and wherein the fluorescent label is FITC.47. A nucleic acid encoding the heavy chain and light chain of the antibody of .48. An expression vector comprising the nucleic acid of . ...

Подробнее
Номер записи: 50
14-01-2021 дата публикации

Biological devices and methods of use thereof for the detection of amyloid proteins

Номер: US20210011029A1
Автор: Diana VASQUEZ FORERO, Juliana LONDONO MURILLO, Raul CUERO RENGIFO
Принадлежит: Biocapital Holdings LLC

Described herein are devices and methods for simultaneously expressing amyloid precursor protein and TonB protein. These devices and methods increase the production of these two proteins while also minimizing costs, making the proteins more widely accessible for medical research purposes, including the development of diagnostic tests for numerous diseases associated with elevated production of amyloid proteins. The amyloid precursor protein and TonB produced by the devices and methods described herein, as well as the devices themselves, can be used in experiments designed to model the interactions between metals and amyloids such as β-amyloid that are characteristic of numerous diseases such as Alzheimer's. Finally, provided herein are diagnostic tests that can detect Alzheimer's disease in samples from patients; the tests are sensitive enough to identify diseases such as Alzheimer's even at pre-clinical stages, before the appearance of symptoms.

Подробнее
Номер записи: 51
03-02-2022 дата публикации

SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER

Номер: US20220031695A1
Автор: Bivona Trever G., NEEL Dana, NICHOLS Robert J.
Принадлежит:

The present disclosure provides methods of treating diseases or disorders using allosteric inhibitors of SHP2 and to methods and diagnostic tests for identifying subjects likely to respond to such allosteric inhibitors of SHP2. In particular, the present disclosure provides diagnostic and therapeutic uses related to certain Receptor Tyrosine Kinase (RTK) mutations that are indicative of sensitivity to allosteric SHP2 inhibitors. 1. A method for identifying whether a subject has a cancer that is sensitive to SHP2 inhibition , the method comprising determining whether the cancer comprises one or more cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation , and , if so , identifying the subject as having a cancer that is sensitive to SHP2 inhibition.2. (canceled)3. A method for killing cancer cells with a SHP2 inhibitor , the method comprising the steps of:a. determining whether the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation; andb. contacting the cancer cells with the SHP2 inhibitor if the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation.4. A method for treating a patient with a SHP2 inhibitor , wherein the patient has cancer , the method comprising the steps of: i. obtaining or having obtained a biological sample from the patient; and', 'ii. performing or having performed an assay on the biological sample to determine if the patient has a tumor comprising one or more cells that contain an oncogenic tyrosine kinase fusion that causes MAPK activation; and, 'a. determining whether the patient has a SHP2-sensitive cancer byb. administering the SHP2 inhibitor to the patient if the patient has a tumor comprising one or more cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation.5. The method of claim 4 , wherein the SHP2 inhibitor is selected from (i) NSC-87877; (ii) TN0155 claim 4 , (iii) of any one of Formula I claim 4 , of Formula II claim 4 , ...

Подробнее
Номер записи: 52
18-01-2018 дата публикации

METHODS OF TREATING UREA CYCLE DISORDERS

Номер: US20180015065A1
Автор: MOKHTARANI Masoud, SCHARSCHMIDT Bruce
Принадлежит:

The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. 120-. (canceled)21. A method of treating a urea cycle disorder (UCD) in a subject in need thereof who is less than two years of age comprising:a) administering glyceryl tri-[4-phenylbutyrate] to the subject whose urinary PAGN level is above 9000 μg/ml at the previously administered dosage, orb) administering an adjusted dosage of the glyceryl tri-[4-phenylbutyrate] to the subject whose urinary PAGN level is below 9000 μg/ml.22. The method of claim 21 , wherein the dosage of glyceryl tri-[4-phenylbutyrate] is administered orally.23. The method of claim 21 , wherein the effective dosage is 5 to 12.4 g/m/day.24. The method of claim 23 , wherein the effective dosage is at or about 7 to 9.5 g/m/day claim 23 , 7.5 to 9 g/m/day claim 23 , 8.0 to 8.5 g/m/day claim 23 , or 8.3 to 8.5 g/m/day.25. The method of claim 24 , wherein the effective dosage is at or about 8.02 or 8.35 g/m/day.26. The method of claim 21 , wherein the subject has not previously been administered one or more dosages of glyceryl tri-[4-phenylbutyrate].27. The method of claim 21 , wherein the subject in need thereof lacks systemic control of endogenous blood ammonia levels.28. A method of assessing compliance in a subject suffering from a urea cycle disorder (UCD) who is less than two years of age comprising:a) testing urinary PAGN level of the subject; andb) administering glyceryl tri-[4-phenylbutyrate] to the subject whose ...

Подробнее
Номер записи: 53
21-01-2016 дата публикации

Methods of Treating Acute Kidney Injury

Номер: US20160015701A1
Автор: Andress Dennis, Zager Richard A.
Принадлежит:

Methods are provided for treating acute kidney injury in a subject, particularly ischemia-induced kidney injury and/or hypoxia-induced kidney injury. The methods comprise administering to the subject an ETA receptor antagonist, such as atrasentan or a pharmaceutically acceptable salt thereof. Methods of diagnosing and treating such kidney injuries are also provided. Methods of reducing or preventing loss of kidney function and/or renal mass or volume, and methods of delaying progression to chronic kidney disease are also provided.

Подробнее
Номер записи: 54
15-01-2015 дата публикации

METHODS FOR ASSESSING RISK FOR CANCER USING BIOMARKERS

Номер: US20150017638A1
Автор: RHIM ANDREW D., Stanger Ben Z.
Принадлежит: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

The present disclosure is directed to methods and kits for detecting, characterizing, preventing, and treating cancer, e.g., pancreatic cancer, or inflammation, by determining the presence of circulating epithelial in a biological sample and further identifying the tissue of origin using a tissue-specific biomarker, e.g., Pdx-1. 1. A method of assessing whether a subject has or is at risk for developing an epithelial cancer , comprising:(a) determining the presence of one or more circulating epithelial cells in a biological fluid sample obtained from the subject,wherein the presence of the circulating epithelial cells in the biological fluid sample is an indication that the subject has or is at risk for developing an epithelial cancer.2. The method of claim 1 , wherein the epithelial cancer is selected from the group consisting of pancreatic cancer claim 1 , kidney cancer claim 1 , renal cell carcinoma claim 1 , urogenital cancer claim 1 , urothelial carcinoma of the urinary bladder claim 1 , urothelial carcinoma of the kidney claim 1 , urothelial carcinoma of the renal pelvis claim 1 , urothelial carcinoma of the ureter claim 1 , prostate cancer claim 1 , lung carcinoma claim 1 , non-small cell lung carcinoma claim 1 , small cell lung carcinoma claim 1 , neuroendocrine carcinoma claim 1 , carcinoid tumor claim 1 , breast carcinoma claim 1 , ductal breast carcinoma claim 1 , lobular breast carcinoma claim 1 , mixed ductal and lobular breast carcinoma claim 1 , thyroid carcinoma claim 1 , papillary thyroid carcinoma claim 1 , follicular thyroid carcinoma claim 1 , medullary thyroid carcinoma claim 1 , brain cancer claim 1 , meningioma claim 1 , astrocytoma claim 1 , glioblastoma claim 1 , cerebellum tumors claim 1 , medulloblastoma claim 1 , ependymoma claim 1 , ovarian carcinoma claim 1 , ovarian serous carcinoma claim 1 , ovarian mucinous carcinoma claim 1 , ovarian endometrioid carcinoma claim 1 , cervical cancer claim 1 , cervical squamous cell carcinoma claim 1 ...

Подробнее
Номер записи: 55
17-01-2019 дата публикации

COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS

Номер: US20190015444A1
Автор: Jain Isha, Mootha Vamsi K., Zapol Warren M., Zazzeron Luca
Принадлежит:

Methods of promoting hypoxia or the hypoxia response for the treatment or prevention of mitochondrial dysfunction and oxidative stress disorders are described. Methods for screening for targets of mitochondrial dysfunction and oxidative stress disorders are also described. 1. A method of treating or preventing mitochondrial dysfunction in a subject in need thereof , the method comprising increasing the activity of a hypoxia response in the subject.29-. (canceled)10. The method of claim 1 , wherein the method comprises administration of a PHD inhibitor.1114-. (canceled)15. A method of treating or preventing mitochondrial dysfunction in a subject in need thereof claim 1 , the method comprising administering to the subject by inhalation a therapeutically effective amount of a therapeutic gas comprising between 5 to 20% O.1636-. (canceled)37. A method of treating or preventing mitochondrial dysfunction in a subject in need thereof claim 1 , the method comprising causing the subject to breathe a therapeutically effective amount of air in a hypobaric chamber.3840-. (canceled)41. The method of claim 15 , wherein the subject has a mitochondrial disorder.42. The method of claim 41 , wherein the mitochondrial disorder is a monogenic mitochondrial disorder.43. The method of claim 42 , wherein the mitochondrial disorder is characterized by a mutation in a gene selected from the group consisting of AARS2 claim 42 , AASS claim 42 , ABAT claim 42 , ABCB6 claim 42 , ABCB7 claim 42 , ABCD1 claim 42 , ACACA claim 42 , ACAD8 claim 42 , ACAD9 claim 42 , ACADM claim 42 , ACADS claim 42 , ACADSB claim 42 , ACADVL claim 42 , ACAT1 claim 42 , ACO2 claim 42 , ACSF3 claim 42 , ACSL4 claim 42 , ADCK3 claim 42 , ADCK4 claim 42 , AFG3L2 claim 42 , AGK claim 42 , AGXT claim 42 , AIFM1 claim 42 , AK2 claim 42 , ALAS2 claim 42 , ALDH18A1 claim 42 , ALDH2 claim 42 , ALDH3A2 claim 42 , ALDH4A1 claim 42 , ALDH5A1 claim 42 , ALDH6A1 claim 42 , ALDH7A1 claim 42 , AMACR claim 42 , AMT claim 42 , APOPT1 ...

Подробнее
Номер записи: 56
17-01-2019 дата публикации

METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE AND NEUROINFLAMMATORY CONDITIONS

Номер: US20190015480A1
Автор: Fu Kit Yu, Ip Nancy Yuk-Yu, Liew Foo Yew
Принадлежит:

Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions. 134.-. (canceled)35. A method for treating Alzheimer's disease in a subject in need thereof , comprising administering to the subject an effective amount of a composition comprising IL-33 and one or more additional agents selected from the group consisting of donepezil , rivastigmine , galantamine , memantine , aducanumab , rosiglitazone , bexarotene , losartan , and rhynchophylline.36. The method of claim 35 , wherein the additional agent is memantine.37. The method of claim 35 , wherein the IL-33 protein comprises an amino acid sequence at least 85% identity to SEQ ID NO: 1 claim 35 , SEQ ID NO: 2 claim 35 , SEQ ID NO: 3 claim 35 , or SEQ ID NO: 4 claim 35 , or functional fragments or variants thereof.38. The method of claim 35 , wherein IL-33 protein selected from the group consisting of SEQ ID NO: 1 claim 35 , SEQ ID NO: 2 claim 35 , a polypeptide having at least 85% identity to SEQ ID NO: 1 claim 35 , and a polypeptide having at least 85% identity to SEQ ID NO: 2.39. The method of claim 35 , wherein the therapeutically effective dosage of IL-33 in the composition is from about 0.000001 mg to about 0.001 mg per kilogram body weight per day.40. A method for increasing transcription of an Aβ receptor or reducing soluble AP levels in a subject in need thereof claim 35 , comprising administering to the subject an effective amount of a composition comprising IL-33.41. The method of claim 40 , wherein the Aβ receptor comprises a Toll like receptor 2 (TLR2) claim 40 , a low density lipoprotein receptor (LDLR) claim 40 , or a macrophage scavenger receptor 1 (MSR1).42. The method of claim 40 , wherein the subject suffers from or is at risk of suffering from Alzheimer's disease claim 40 , mild cognitive impairment claim 40 , Parkinson's disease ...

Подробнее
Номер записи: 57
03-02-2022 дата публикации

IMMUNOHISTOCHEMICAL STAINING FOR GSK-3

Номер: US20220034766A1
Автор: UGOLKOV Andrey
Принадлежит:

Methods of using immunohistochemical staining to identify cells expressing GSK-3 and use of such methods in treating disease are disclosed. 1. A method of treating a disease in a subject in need thereof , the method comprising: a) obtaining a tissue sample from the subject; b) measuring the expression level of a GSK-3 isoform in the sample , wherein the measuring is performed by immunohistochemical staining; c) comparing the expression level of the GSK-3 isoform in the tissue sample with the expression level of that GSK-3 isoform in a control sample; and d) administering an effective amount of an inhibitor of the GSK-3 isoform to the subject if an elevated expression level of the GSK-3 isoform in the tissue sample is detected when compared to the expression level of the GSK-3 isoform in the control sample.2. The method of claim 1 , wherein the expression level of GSK-3 isoform is nuclear expression.3. The method of claim 1 , wherein the expression level of GSK-3 isoform is cytoplasmic expression.4. The method of claim 1 , wherein the expression level of GSK-3 isoform is nuclear and cytoplasmic expression.5. The method of claim 1 , wherein the GSK-3 isoform is GSK-3β.6. The method of claim 1 , wherein the inhibitor of the GSK-3 isoform is 9-ING-41 claim 1 , tideglusib claim 1 , or LY2090314.7. The method of claim 6 , wherein the inhibitor of the GSK-3 isoform is 9-ING-41.8. The method of claim 1 , wherein the GSK-3 isoform is GSK-3α.9. The method of claim 1 , wherein the disease is cancer.10. The method of claim 9 , wherein the tissue sample is a tumor sample.11. The method of claim 9 , wherein the cancer is breast cancer claim 9 , brain cancer claim 9 , esophagus cancer claim 9 , stomach cancer claim 9 , lung cancer claim 9 , liver cancer claim 9 , kidney cancer claim 9 , thyroid gland cancer claim 9 , spleen cancer claim 9 , pancreas cancer claim 9 , large bowel cancer claim 9 , skin cancer claim 9 , ovarian cancer claim 9 , uterus cancer claim 9 , prostate cancer ...

Подробнее
Номер записи: 58
03-02-2022 дата публикации

USE OF CIRCULATING TUMOR CELL MITOTIC INDEX IN CANCER STRATIFICATION AND DIAGNOSTICS

Номер: US20220034888A1
Автор: ADAMS Daniel, Tang Cha-Mei
Принадлежит: CREATV MICROTECH INC.

Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient. 1. A method for monitoring the effectiveness of treatment in a subject having cancer , wherein the method comprises:(a) obtaining a first population of CTCs from a first biological sample of a subject having cancer,(b) screening the first population for cells in a mitotic cell cycle phase,(c) administering a cancer treatment to the subject,(d) obtaining a second population of CTCs from a second biological sample of the subject after treatment, and(e) screening the second population for cells in a mitotic cell cycle phase,wherein an increase in the number of mitotic CTCs in the second population versus the first population, or an increase in the mitotic index calculated for the second population versus the first population, suggests the treatment is ineffective.2. The method of claim 1 , wherein the biological sample is selected from the group consisting of peripheral blood claim 1 , blood claim 1 , lymph nodes claim 1 , bone marrow claim 1 , cerebral spinal fluid claim 1 , and urine claim 1 , and wherein the first and second biological samples are from the same source.3. The method of claim 2 , wherein the first and second biological samples are at least about 7.5 mL of peripheral blood.4. The method of claim 1 , wherein the cancer is carcinoma and the CTCs are characterized by one or more of the following characteristics:(a) diameter of between about 7 and 25 microns,(b) presence ...

Подробнее
Номер записи: 59
03-02-2022 дата публикации

Method of Determining Disease State Risk

Номер: US20220034895A1
Автор: Paul L. Wood
Принадлежит: Lincoln Memorial University

A method for determining colorectal cancer risk includes obtaining a blood sample of the subject, isolating serum or EDTA plasma from the blood sample, analyzing the serum or EDTA plasma to determine plasma levels of very long chain dicarboxylic acid (VLCDCA 28:4), comparing the determined plasmas level of VLCDCA 28:4 of the subject with a predetermined range of plasma levels of VLCDCA 28:4 of diagnosed subjects having colorectal cancer, and determining a colorectal cancer risk exists when the determined plasma level of VLCDCA 28:4 is within the predetermined range of plasma levels of VLCDCA.

Подробнее
Номер записи: 60
03-02-2022 дата публикации

System and Method of Automatically Preparing and Analyzing Urine Samples for Identifying Cancer Cells

Номер: US20220034919A1
Автор: Zarate Alfredo R.
Принадлежит:

A system and method of automatically preparing and analyzing urine samples for identifying cancer cells is able to complete conventional diagnostic tasks without lab technicians, cytopathologists, or other medical professionals. The method is provided with at least one source sample, at least one manipulator arm, at least one centrifuge, at least one electronic microscope, and at least one unitary controller. The method is further provided with a cytopathological index containing a visual characteristic database and identification confidence threshold rubrics supporting the automation of visual analyses typically performed manually with a conventional microscope. This method is further provided with a data processing function, wherein data stemming from multiple testing cycles may be collated, formatted, and presented for use by medical professionals in determining and projecting the effectiveness of a course of treatment. 1. A method of automatically preparing and analyzing urine samples for identifying cancer cells , the method comprises the steps of:(A) providing at least one source sample, at least one manipulator arm, at least one centrifuge, at least one electronic microscope, and at least one unitary controller, wherein the unitary controller is communicably coupled to the manipulator arm, the centrifuge, and the electronic microscope, wherein a cytopathological index is stored on the unitary controller;(B) preparing the source sample into a plurality of sample tubes with the manipulator arm, wherein each sample tube includes a sample identification;(C) loading the sample tubes into the centrifuge with the manipulator arm;(D) executing a separation process on the sample tubes with the centrifuge;(E) removing the sample tubes from the centrifuge with the manipulator arm;(F) extracting a plurality of sediment samples with the manipulator arm, wherein each sample tube is associated to a corresponding sediment sample from the plurality of sediment samples;(G) ...

Подробнее
Номер записи: 61
21-01-2021 дата публикации

Method for Detecting and Monitoring Exhaled Breath

Номер: US20210015399A1
Автор: Gouma Pelagia I.
Принадлежит: Ohio State Innovation Foundation

A method for measuring levels of specific biomarkers in exhaled breath. Specific compounds such as nitric oxide and isoprene can be monitored from a subject's breath. The resultant measurements can provide indications of the subject's medical condition, or response to an applied stress. 1. A method for measuring levels of nitric oxide and isoprene in exhaled breath from a subject comprising:exhaling breath into a receiver;transferring the breath into a breath processing unit connected to the receiver and heated within a range of 25 to 400° C.;{'sub': 3', '3', '3', '3, 'contacting the exhaled breath with a surface of γ-WOinside the breath processing unit which responds to nitric oxide, and a surface of h-WOinside the breath processing unit which responds to isoprene to alter an electrical property of the γ-WOsurface and the h-WOsurface; and'}{'sub': 3', '3, 'correlating the electrical property of the γ-WOsurface with a concentration of nitric oxide in the exhaled breath, and the electrical property of the h-WOsurface with a concentration of isoprene in the exhaled breath.'}2. The method of wherein the receiver and the breath processing unit are integrated into a single combined unit.3. The method of wherein the surface of the γ-WOand the surface of h-WOare separately coupled to electrodes of platinum or gold.4. The method of wherein the electrodes are coupled to an alumina substrate.5. The method of wherein the breath processing unit is heated within a range of 150 to 400° C.6. The method of wherein the breath processing unit is heated within a range of 200 to 350° C.7. The method of wherein the breath processing unit is heated within a range of 250 to 350° C.8. The method of wherein the levels of nitric oxide and isoprene are monitored continuously.9. The method of wherein the subject is a fighter pilot operating an aircraft.10. The method of to evaluate for high altitude pulmonary edema.11. The method of to evaluate for asthma.12. The method of to evaluate for an ...

Подробнее
Номер записи: 62
15-01-2015 дата публикации

BIOMARKERS FOR DIAGNOSING ISCHEMIA

Номер: US20150018234A1
Автор: Jickling Glen C., Sharp Frank
Принадлежит: The Regents of the University of California

The present invention provides methods and compositions for diagnosing and predicting the occurrence of ischemia. For example, the present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient neurological events (TNE) as ischemic or non-ischemic. 1. A method for diagnosing transient cerebral ischemia or a predisposition for experiencing transient cerebral ischemia , the method comprising: determining a level of expression of a plurality of ischemia-associated biomarkers in a biological sample from a patient , wherein an increase or decrease of the level of expression compared to a control indicates that the patient has suffered or is at risk of experiencing transient cerebral ischemia , wherein the plurality of ischemia-associated biomarkers is selected from the biomarkers set forth in Tables 3 and 5 , thereby diagnosing transient cerebral ischemia or a predisposition for experiencing transient cerebral ischemia.2. A method for diagnosing a transient neurological event (TNE) as ischemic or non-ischemic , the method comprising: determining a level of expression of a plurality of ischemia-associated biomarkers in a biological sample from a patient , wherein an increase or decrease of the level of expression compared to a control indicates that the patient has suffered or is at risk of experiencing transient cerebral ischemia , wherein the plurality of ischemia-associated biomarkers is selected from the biomarkers set forth in Tables 3 and 5 , thereby diagnosing a transient neurological event (TNE) as ischemic or non-ischemic.3. A method for identifying the occurrence or a predisposition for experiencing ischemia , the method comprising: determining a level of expression of a plurality of ischemia-associated biomarkers in a biological sample from a patient , wherein an increase or decrease of the level of expression compared to a control indicates that the patient has suffered or is at risk of experiencing ischemia , ...

Подробнее
Номер записи: 63
18-01-2018 дата публикации

Self-assembling ultrashort aliphatic depsipeptides for biomedical applications

Номер: US20180016304A1
Автор: Charlotte A. E. Hauser, Michael R. Reithofer, Yihua LOO
Принадлежит: Agency for Science Technology and Research Singapore

The present invention relates to ultrashort depsipeptides which are capable of self-assembling into hydrogels. One preferred embodiment is of Ac-ILVaGK-NH 2 , where a represents lactic acid. The invention also relates to the use of these depsipeptides in formulating hydrogels, co-gels or co-hydrogels, and pharmaceutical compositions or biomedical device or surgical implants or kits comprising these depsipeptides for various therapeutic applications such as regenerative medicine, tissue regeneration and tissue re-placement.

Подробнее
Номер записи: 64
21-01-2016 дата публикации

Process for evaluating active agent(s) capable of preserving the functionality of epithelial stem cells

Номер: US20160018388A1
Автор: Bruno Bernard, Michelle Rathman Josserand
Принадлежит: LOreal SA

The present invention relates to a process for evaluating in vitro at least one active agent capable of preserving the functionality of epithelial stem cells, in particular of maintaining or stimulating the growth and/or the density and/or the renewal of a keratin material, consisting in determining the ability of the active agent(s) to mimic a hypoxic state in the keratin material, the active agent(s) being capable of increasing the expression of at least carbonic anhydrase IX as biological marker of hypoxia, in the keratin material treated with the active agent(s) compared with the keratin material not treated with the active agent(s). It also relates to the use of such a process.

Подробнее
Номер записи: 65
18-01-2018 дата публикации

Method for selecting patients responsive for cancer treatments

Номер: US20180017547A1
Автор: Käämbre Tuuli, Koit Andre
Принадлежит:

The present invention is directed to a method of quantifying intracellular metabolite effluxes in permeabilized cancer cells for selecting cancer patients responsive for a cancer treatment, the method comprising the steps of: a) providing a sample of cancer cells taken from a patient; b) permeabilizing said cancer cells; c) incubating said permeabilized cancer cells in a reaction medium for a period of time allowing biological activity of intracellular organelles and accumulation of metabolites produced by said activity into the reaction medium in the presence of a substrate or substrates relating to a metabolite efflux or effluxes of interest, wherein said substrates used are at least glutamine and pyruvate; d) determining the quantity of metabolites relating to said metabolite efflux or effluxes of interest accumulated in the reaction medium during step c); and e) comparing the amounts of metabolites determined in step d) to equal measurements performed on control samples of the same tissue type and assessing the aggressiveness of the cancer cells or the treatment response of the cancer cells to a drug affecting a metabolic pathway or pathways relating to said metabolite efflux or effluxes of interest. 1. A method of quantifying intracellular metabolite effluxes in permeabilized cancer cells for selecting cancer patients responsive for a cancer treatment , the method comprising the steps of:a) providing a sample of cancer cells taken from a patient;b) permeabilizing said cancer cells;c) incubating said permeabilized cancer cells in a reaction medium for a period of time allowing biological activity of intracellular organelles and accumulation of metabolites produced by said activity into the reaction medium in the presence of a substrate or substrates relating to a metabolite efflux or effluxes of interest, wherein the substrates used are at least glutamine and pyruvate;d) determining the quantity of metabolites relating to said metabolite efflux or effluxes of ...

Подробнее
Номер записи: 66
18-01-2018 дата публикации

COMPOUNDS AND METHODS FOR THE DETECTION OF CALPROTECTIN

Номер: US20180017576A1
Автор: Roth Johannes, Vogl Thomas
Принадлежит:

The present invention relates to a compound for use in a method of diagnosing acute or chronic inflammatory diseases in a subject. In particular, the present invention provides a S100A8/S100A9 heterodimer standard comprising at least one mutation in low- or high-affinity calcium binding hand that can be used in a method of detecting biomarkers of inflammation in a sample. Accordingly, the S100A8/S100A9 heterodimer standard allows for standardizing quantitative immunoassays and quantifying S100A8/S100A9 heterodimers. 1. A method for detecting a S100A8/S100A9 heterodimer in a sample , the method comprising the use of an S100A8/S100A9 heterodimer standard which comprises at least one mutation in at least one of the following regions:a) the high-affinity calcium binding hand of S100A9,b) the low-affinity calcium binding hand of S100A9,c) the high-affinity calcium binding hand of S100A8, ord) the low-affinity calcium binding hand of S100A8.2. The method of claim 1 , wherein the S100A8/S100A9 heterodimer standard does not tetramerize to (S100A8/S100A9)tetramers.3. The method of any one of the preceding claims claim 1 , wherein the S100A8/S100A9 heterodimer standard comprises at least one mutation in:a) the amino acid sequence ranging from amino acid position 63 to amino acid position 79 of the human S100A9 protein of Uniprot/Swissprot accession no. P06702 (SEQ ID NO: 1),b) the amino acid sequences ranging from amino acid position 20 to amino acid position 38 of the human S100A9 protein of Uniprot/Swissprot accession no. P06702 (SEQ ID NO: 1),c) the amino acid sequences ranging from amino acid position 55 to amino acid position 71 of the human S100A8 protein of Uniprot/Swissprot accession no. P05109 (SEQ ID NO: 2), ord) the amino acid sequences ranging from amino acid position 20 to amino acid position 38 of the human S100A8 protein of Uniprot/Swissprot accession no. P05109 (SEQ ID NO: 2), and combinations thereof.4. The method of claim 3 , wherein the S100A8/S100A9 ...

Подробнее
Номер записи: 67
21-01-2021 дата публикации

DETECTION OF OLIGOSACCHARIDES

Номер: US20210017570A1
Автор: Brown Jillian R., Crawford Brett E., Glass Charles A.
Принадлежит: Biomarin Pharmaceutical Inc.

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS IIIA or MPS IIIB disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS IIIA or MPS IIIB disorder relative to individuals without the MPS IIIA or MPS IIIB disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; andwherein the biomarker is selected from a group consisting of{'sub': '3', 'Formula III: [GlcNS-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula IV: [GlcNS-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula V: [GlcNAc-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula VI: [GlcNAc-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula VIII: [GlcN-GlcA-GlcN(Ac)0-1](SOR)0-4;'}{'sub': '3', 'Formula IX: [GlcNAc6S-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula X: [GlcNAc6S-GlcA-GlcN(Ac)0-1](SOR)0-2;'}GlcN-IdoA-GlcNAc;GlcN-IdoA2S-GlcNAc;GlcN-IdoA-GlcNS;GlcN-IdoA-GlcNAc6S;GlcN-IdoA2-GlcNAc6S; andGlcN-IdoA-GlcNS6S.32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)-1](SOR); or ...

Подробнее
Номер записи: 68
21-01-2021 дата публикации

SYSTEMS AND METHODS TO DIAGNOSE SARCOIDOSIS AND IDENTIFY MARKERS OF THE CONDITION

Номер: US20210017602A1
Автор: Fernandez-Madrid Felix, Li Jia, Rosati Rita, Samavati Lobelia, Talwar Harvinder S.
Принадлежит:

Systems and methods to diagnose sarcoidosis are described. In addition to diagnosing sarcoidosis, the systems and methods can distinguish sarcoidosis from tuberculosis. Further disclosed is a cDNA library and methods of its use for reliably identifying sarcoidosis markers. 1. A kit comprising:a protein that binds Small inducible cytokine A21 precursor (CCL21); Methionine aminopeptidase 1 (Metap1); Activated RNA polymerase II transcription cofactor variant 4 (PC4); RNA methyltransferase (CLI_3190); Tumor necrosis factor receptor superfamily member 21 precursor (TNFRSF21); Monocyte differentiation antigen CD14 (CD14); DnaJ (Hsp40) homolog subfamily C member 1 precursor (DNAJC1); Amyloid β A4 precursor protein binding family B member 1-interacting protein (APBB1); Fibroblast growth factor binding protein 2 precursor (FGFBP-2); or SH3 domain-containing YSC84 like protein 1 (SH3YL1) and a detectable label;a nucleic acid that binds a gene encoding CCL21; Metap1; PC4; CLI_3190; TNFRSF21; DNAJC1; APBB1; FGFBP-2; or SH3YL 1 and a detectable label;{'i': Mycobacterium tuberculosis', 'Homo sapiens, 'a protein that binds Ferredoxin (Fed A); WDFY3 protein (WDFY3); Membrane protein (MFS); Leucine rich PPR-motif containing protein (LRPPRC); HLA-DR alpha (HLA-DR); Transketolase (TKT); Dihydroxy acid dehydratase (Rv0189C); Chain A (BfrA); Disabled homolog 2 isoform 2 (DAB2); or Transcription elongation factor B polypeptide 2 isoform () (TCEB2) and a detectable label; or'}a nucleic acid that binds a gene encoding Fed A; WDFY3; MFS; LRPPRC; HLA-DR; TKT; Rv0189C; BfrA; DAB2; or TCEB2 and a detectable label.2. The kit according claim 1 , wherein the kit comprises more than one protein claim 1 , and the proteins comprise antibodies claim 1 , epitopes or mimotopes.3. The kit according to claim 1 , wherein the detectable label comprises a radioactive isotope claim 1 , enzyme claim 1 , dye claim 1 , fluorescent dye claim 1 , magnetic bead claim 1 , or biotin.4. The kit according claim 1 , ...

Подробнее
Номер записи: 69
16-01-2020 дата публикации

Biomarkers for disease progression in melanoma

Номер: US20200018756A1
Автор: Marie Labus, Penny Lovat, Robert Ellis
Принадлежит: Amlo Biosciences Ltd

The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.

Подробнее
Номер записи: 70
25-01-2018 дата публикации

METHODS OF TREATING UREA CYCLE DISORDERS

Номер: US20180021292A1
Автор: MOKHTARANI Masoud, SCHARSCHMIDT Bruce
Принадлежит:

The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. 120.-. (canceled)21. A method for determining or adjusting an effective dosage of a phenylacetic acid (PAA) prodrug to be administered to a subject with a urea cycle disorder , comprising:calculating the body surface area (BSA) of the subject; and{'sup': 2', '2, 'administering an effective dosage of the PAA prodrug to the subject wherein the effective dosage of the PAA prodrug is a first dosage if the BSA is at or above 1.3 mor a second dosage if the BSA is below 1.3 m, and wherein the second dosage is higher than the first dosage.'}22. The method of claim 21 , wherein the PAA prodrug is glyceryl tri-[4-phenylbutyrate].23. The method of claim 21 , wherein the subject has previously been administered an initial dosage of an initial PAA prodrug.24. The method of claim 23 , wherein the initial PAA prodrug is glyceryl tri-[4-phenylbutyrate].25. The method of claim 23 , wherein the initial dosage of the glyceryl tri-[4-phenylbutyrate] is 5 to 12.4 g/m/day.26. The method of claim 25 , wherein the effective dosage of the PAA prodrug is 5.33 to 8.79 g/m/day.27. The method of claim 26 , wherein the PAA prodrug is glyceryl tri-[4-phenylbutyrate].28. The method of claim 25 , wherein the effective dosage of the PAA prodrug is 6.25 to 9.9 g/m/day.29. The method of claim 28 , wherein the PAA prodrug is glyceryl tri-[4-phenylbutyrate].30. The method of claim 21 , wherein the subject is under the age of ...

Подробнее
Номер записи: 71
28-01-2016 дата публикации

HUMAN MONOCLONAL ANTIBODIES THAT BIND INSULIN-LIKE GROWTH FACTOR (IGF) I AND II

Номер: US20160024199A1
Автор: Dimitrov Dimiter S., Zhao Qi, Zhu Zhongyu
Принадлежит: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer. 1. An isolated human monoclonal antibody , or an antigen binding fragment thereof , comprising a heavy chain variable region and a light chain variable region , and wherein the heavy chain variable region comprises the amino acid sequence set forth as amino acids 26-33 of SEQ ID NO: 7 , amino acids 51-58 of SEQ ID NO: 7 , and amino acids 97-109 of SEQ ID NO: 7 ,wherein SEQ ID NO: 7 is the amino acid sequence set forth as:{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16, 'QVQLQQXGAEVKMPGSSVKXSCXASGGTFSSYAISWXRQAPGQGLE WMGGIIPTLXIVKYXXKFQGRVTITADXSXXXYMELSXLXSEDTAV YYCAGGPRGYSYNFDXWXQGTXVTVSS, wherein Xis L or P; Xis V or I; Xis K or R; Xis V or M; Xis G or S; Xis A or S; Xis Q or P; Xis K or E; Xis T or K; Xis S or G; Xis A or V; Xis S or N; Xis G or R; Xis N or E; Xis G or S; and Xis L or M,'}{'sub': d', 'd, 'and wherein the antibody specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (K) of 200 pM or less and that specifically binds IGF-I with an equilibrium dissociation constant (K) of 200 pM or less, and wherein the antibody inhibits phosphorylation of the insulin-like growth factor ...

Подробнее
Номер записи: 72
17-04-2014 дата публикации

System and Method for Diagnosis and Treatment

Номер: US20140107086A1
Автор: Myron Rapkin, Neil David THEISE, Randice Lisa Altschul, Rebecca O'brien
Принадлежит: POP TEST CORTISOL LLC

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

Подробнее
Номер записи: 73
24-01-2019 дата публикации

APPARATUS AND METHOD FOR DETECTION OF TUMOUR CELLS AND CIRCULATING TUMOUR CELLS

Номер: US20190022652A1
Автор: Garcia Algar Manuel, Garcia Rico Eduardo Manuel, Gomez de Pedro Sara, Nazarenus Moritz, Sagales Juan, Villanueva Leal Carlos, Xie Hainan
Принадлежит:

The invention relates to an apparatus and method of detecting and quantifying the number of circulating tumour cells (CTCs) and/or tumour cells (TCs) from a liquid biopsy by using a hyperoxic environment and incubation with a fluorophore-labelled metabolic indicator (fluorophore-labelled 2-D-glucose derivative) and microfluidic chips. 115-. (canceled)17. The method according to claim 16 , wherein the fluorophore-labelled metabolic indicator is 2-(N-(7-nitrobenz-2-oxa-1 claim 16 ,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG).18. The method according to claim 16 , which is carried out using a device comprising a set of microfluidic chips for the detection of circulating tumour cells (CTCs) and/or tumour cells (TCs) in a liquid sample comprising: i. at least two inlets, wherein one inlet is for introducing the liquid sample and the other inlet(s) is/are for introducing a solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen or components thereof, all the inlets converging in a micromixer for the mixture and incubation of the liquid sample and the solution comprising a fluorophore-labelled metabolic indicator saturated with oxygen, and', 'ii. an outlet to allow the exit of the mixture to the purification chip;, 'a. a mixing chip comprising'} i. an inlet for the entrance of the mixture,', 'ii. a main microchannel with constrictions and lateral bifurcation microchannels for the extraction of the fluorophore-labelled metabolic indicator not accumulated in cells while avoiding the removal of cells,', 'iii. a main microchannel outlet for the exit of cells to the detection chip, and', 'iv. further lateral bifurcation outlets for the exit of the extracted fluorophore-labelled metabolic indicator; and, 'b. a purification chip comprising'}c. a detection chip comprising three inlets, a first central inlet for the entrance of cells and the second and third inlets for the entrance of a solution for cell focusing, wherein the second and third inlets are ...

Подробнее
Номер записи: 74
26-01-2017 дата публикации

ISOTYPING IMMUNOGLOBULINS USING ACCURATE MOLECULAR MASS

Номер: US20170023584A1
Автор: Barnidge David R., Dasari Surendra, Mills John R., Murray David L.
Принадлежит: Mayo Foundation for Medical Education and Research

This document relates to methods for detecting and quantifying heavy and light chains of immunoglobulin using mass spectrometry techniques. 1. A method for detecting immunoglobulin light chains , immunoglobulin heavy chains , or mixtures thereof in a sample , the method comprising:a) providing a sample comprising an immunoglobulin light chain, an immunoglobulin heavy chain, or mixtures thereof;b) immunopurifying the sample; andc) subjecting the immunopurified sample to a mass spectrometry technique to obtain a mass spectrum of the sample.2. The method of claim 1 , wherein immunopurifying comprises using an antibody selected from the group consisting of an anti-human IgG antibody claim 1 , an anti-human IgA antibody claim 1 , an anti-human IgM antibody claim 1 , an anti-human IgD antibody claim 1 , an anti-human IgE antibody claim 1 , an anti-human kappa antibody claim 1 , an anti-human lambda antibody claim 1 , and combinations thereof.3. The method of any one of - claim 1 , wherein the antibody is a non-human antibody.4. The method of any one of - claim 1 , wherein the non-human antibody is at least one of a camelid antibody claim 1 , a cartilaginous fish antibody claim 1 , llama claim 1 , sheep claim 1 , goat claim 1 , or a mouse antibody.5. The method of any one of - claim 1 , wherein the antibody is a single domain antibody fragment.6. The method of any one of - claim 1 , wherein the single domain antibody fragment (SDAF) is selected from the group consisting of an anti-human IgG SDAF claim 1 , an anti-human IgA SDAF claim 1 , an anti-human IgM SDAF claim 1 , an anti-human IgD SDAF claim 1 , an anti-human IgE SDAF claim 1 , an anti-human kappa SDAF claim 1 , an anti-human lambda SDAF claim 1 , and combinations thereof.7. The method of any one of - claim 1 , wherein the single domain antibody fragment is derived from a camelid antibody claim 1 , a cartilaginous fish antibody claim 1 , llama claim 1 , a mouse antibody claim 1 , sheep claim 1 , goat claim 1 , or a ...

Подробнее
Номер записи: 75
10-02-2022 дата публикации

Targeted therapies for cancer

Номер: US20220042112A1
Автор: Alan Bryce, David Craig, George Vasmatzis, Jessica Aldrich, John Carpten, Keith Stewart, Michael Barrett, Mitesh Borad, Sara Byron
Принадлежит: Mayo Foundation for Medical Education and Research, Translational Genomics Research Institute TGen

Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.

Подробнее
Номер записи: 76
25-01-2018 дата публикации

METHOD FOR THE ENRICHMENT OF CIRCULATING TUMOR DNA

Номер: US20180024141A1
Автор: Eccleston Mark Edward, HERZOG Marielle, MICALLEF Jacob Vincent
Принадлежит: Belgian Volition SPRL

The invention relates to the use of histone binding agents for detecting, isolating and/or purifying cell free nucleosomes of tumor originor circulating tumor DNA from a biological sample. The invention also relates to methods and kits using said histone binding agents. 1. (canceled)2. A method for isolating circulating cell free nucleosomes of tumor origin from a biological sample by affinity purification wherein said method comprises the steps of:(i) contacting the sample with a histone H3.1 and/or H3.2 and/or H3t binding agent;(ii) isolating bound nucleosomes from the sample; and(iii) analysing the isolated nucleosomes and/or associated DNA.3. The method according to claim 2 , wherein the step of analysing the isolated nucleosomes and/or associated DNA comprises an immunoassay method.4. The method according to claim 2 , wherein the step of analysing the isolated nucleosomes and/or associated DNA comprises a proteomics method.5. The method according to claim 2 , wherein the step of analysing the isolated nucleosomes and/or associated DNA comprises mass spectrometry.6. A method for isolating purified circulating tumor DNA (ctDNA) from a biological sample claim 2 , wherein said method comprises the steps of:(i) isolating circulating cell free nucleosomes containing histone H3.1 and/or H3.2 and/or H3t;(ii) extracting DNA from the nucleosome sample produced in step (i); and(iii) analysing the extracted DNA.7. The method according to claim 6 , wherein the step of analysing the extracted DNA comprises: DNA sequencing claim 6 , methylated DNA sequencing analysis claim 6 , PCR claim 6 , BEAMing claim 6 , NGS (targeted or whole genome) claim 6 , digital PCR claim 6 , cold PCR (co-amplification at lower denaturation temperature-PCR) claim 6 , MAP (MIDI-Activated Pyrophosphorolysis) claim 6 , PARE (personalized analysis of rearranged ends) or Mass Spectrometry.8. An immunoassay method for detecting an epigenetic epitope of tumor derived circulating nucleosomes in a ...

Подробнее
Номер записи: 77
28-01-2021 дата публикации

Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers

Номер: US20210023190A1
Автор: Andrea MAHR, Anita WIEBE, Harpreet Singh, Jens FRITSCHE, Oliver Schoor, Toni Weinschenk
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Подробнее
Номер записи: 78
24-01-2019 дата публикации

COLLAPSIBLE ELEMENT POCKET FORMER

Номер: US20190024187A1
Автор: Sorkin Felix
Принадлежит:

A pocket former may include a pocket former body, the pocket former body having an outer surface. The pocket former may further include a collapsible element, the collapsible element formed on the outer surface of the pocket former body. The collapsible element may extend radially outwardly from the pocket former body. 1. A pocket former comprising:a pocket former body, the pocket former body having an outer surface including at least one pocket former bridge; anda collapsible element, the collapsible element formed on the outer surface of the pocket former body, the collapsible element extending radially outwardly from the pocket former body;wherein the pocket former bridge is adapted to break upon the application of a force on the collapsible element, separating the pocket former body into two or more portions.2. The pocket former of claim 1 , wherein the pocket former body is tapered from a pocket former outer edge to a pocket former inner edge.3. The pocket former of claim 1 , wherein the collapsible element is attached to at least one of the portions.4. The pocket former of claim 1 , wherein the collapsible element has an exterior surface and wherein the exterior surface of the collapsible element has a curved profile.5. The pocket former of claim 4 , wherein the collapsible element has a cross-sectional angle α and a longitudinal angle β claim 4 , and wherein the cross-sectional angle α is smaller than the longitudinal angle β.6. The pocket former of claim 1 , wherein the pocket former body further comprises a flex feature.7. The pocket former of claim 1 , wherein the pocket former bridges are longitudinally oriented along the pocket former body and the portions are longitudinal segments.8. The pocket former of claim 1 , wherein the portions are adapted to flex into an interior of the pocket former after separation.9. The pocket former of claim 5 , wherein the collapsible elements are adapted to retract.10. The pocket form of claim 9 , wherein the collapsible ...

Подробнее
Номер записи: 79
24-01-2019 дата публикации

METHODS OF MEASURING SIGNALING PATHWAY ACTIVITY FOR SELECTION OF THERAPEUTIC AGENTS

Номер: US20190025287A1
Автор: LAING Lance Gavin, SULLIVAN Brian Francis
Принадлежит:

Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided. 1. A method of treating a human subject diagnosed with cancer , the method comprising:administering to the subject at least one targeted therapeutic that is therapeutically active in a signaling pathway in which signaling has been measured in the subject's cancer cells by a method comprising:culturing a sample comprising viable cancer cells obtained from the subject;contacting the sample with at least two sets of paired agents, each set comprised of a first agent that is a targeted therapeutic and a second agent that is an activator that is known to selectively affect the same signaling pathway the first agent is intended to address, wherein each set of paired agents affects a different signaling pathway, so as to upregulate or downregulate the signaling pathway as measured by an effect on cell adhesion or attachment, to produce a sample contacted with at least two sets of paired agents;continuously measuring cell adhesion or attachment of the viable cancer cells in the sample contacted with each set of paired agents, relative to a sample of viable cancer cells obtained from the subject that is contacted with each of the first agents or each of the second agents alone;determining by mathematical analysis of the continuous measurements an output value for each set of paired agents that characterizes ...

Подробнее
Номер записи: 80
24-01-2019 дата публикации

METHODS TO IDENTIFY AND TREAT SUBJECTS HAVING CORTICOSTEROID-RESISTANT INFLAMMATORY DISEASES

Номер: US20190025307A1
Автор: Goleva Elena, Leung Donald Y.M., Li Lingbo
Принадлежит:

The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids. 144.-. (canceled)45. A method to identify a subject having an inflammatory disease resistant to corticosteroid treatment comprising determining the level of phosphorylated MSK1 (p-MSKI) in a biological sample from the subject.46. The method of claim 45 , wherein the step of determining the subject's p-MSK1 level comprises determining the subject's p-MSK1 level claim 45 , wherein an elevated p-MSK1 level in the subject as compared to a control p-MSK1 level indentifies the subject as having an inflammatory disease resistant to corticosteroid treatment.47. The method of wherein the biological sample is selected from the group consisting of urine claim 45 , blood claim 45 , sputum claim 45 , bronchoalveolar lavage (BAL) cells and peripheral blood mononuclear cells (PBMCs).48. The method of claim 45 , wherein the inflammatory disease is selected from the group consisting of inflammatory bowel disease claim 45 , allergic rhinitis claim 45 , sinusitis claim 45 , atopic dermatitis claim 45 , psoriasis claim 45 , arthritis claim 45 , inflammatory lung disease claim 45 , interstitial lung disease claim 45 , sarcoidosis claim 45 , and an autoimmune inflammatory disease.49. (canceled)50. (canceled)51. The method of claim 48 , wherein the inflammatory lung disease is triggered by the subject's exposure to environmental conditions.52. (canceled)53. The method of claim 48 , wherein the inflammatory lung disease is asthma.54. The method of claim 45 , wherein the subject is being administered a non-steroidal anti-inflammatory drug.55. (canceled)56. A method for diagnosing and treating an inflammatory disease resistant to corticosteroid treatment in a subject comprising analyzing a subject sample for the presence of p-MSK1 claim 45 , wherein the subject is diagnosed as having an inflammatory disease resistant to corticosteroid ...

Подробнее
Номер записи: 81
24-01-2019 дата публикации

METHODS FOR DETECTION OF PLASMA CELL DYSCRASIA

Номер: US20190025311A1
Автор: Drozdov Ignat, Kidd Mark, Modlin Irvin Mark
Принадлежит:

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy. 1. A method for detecting a plasma cell dyscrasia in a subject in need thereof , comprising:determining the expression level of at least 32 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 32 biomarkers, wherein the at least 32 biomarkers comprise ASXL1, BHLHE40, BTG2, COPA, FBXW7, GNA13, IL8, JMJD1C, LARS2, MALAT1,MBNL1,MCL1, NFKBIZ (2 splice variants), NR4A1 (2 splice variants), PDE4B, P1AS2, PRKAA1 (2 splice variants), SCYL2 (2 splice variants), SMARCD2, SP1 (2 splice variants), SRSF5, TAGAP, TANK, TLE4, TSC22D3, UBE2J1, and at least one housekeeping gene;normalizing the expression level of each of ASXL1, BHLHE40, BTG2, COPA, FBXW7, GNA13, IL8, JMJD1C, LARS2, MALAT1, MBNL1, MCL1, NFKBIZ (2 splice variants), NR4A1 (2 splice variants), PDE4B, PJAS2, PRKAA1 (2 splice variants), SCYL2 (2 splice variants), SMARCD2, SP1 (2 splice variants), SRSF5, TAGAP, TANK, TLE4, TSC22D3, and UBE2J1 to the expression level of the at least one housekeeping gene, thereby obtaining a normalized expression level of each of ASXL1, BHLHE40, BTG2, COPA, FBXW7, GNA13, IL8, JMJD1C, LARS2, MALAT1,MBNL1,MCL1, NFKBIZ (2 splice variants), NR4A1 (2 splice variants), PDE4B, PJAS2, PRKAA1 (2 splice variants), SCYL2 (2 splice variants), SMARCD2, SP1 (2 splice variants), SRSF5, TAGAP, TANK, TLE4, TSC22D3, and UBE2J1;inputting each normalized expression level into an algorithm to generate a score;comparing the score with a first predetermined cutoff value; andproducing a report, wherein the report identifies the presence of a plasma cell dyscrasia in the subject when ...

Подробнее
Номер записи: 82
28-01-2021 дата публикации

DIAGNOSTIC AND PROGNOSTIC METHODS FOR ESTROGEN-INDUCED CANCERS

Номер: US20210025872A1
Автор: TANWAR Pradeep S.
Принадлежит:

Provided herein are methods for detecting an estrogen-induced cancer in a subject, for identifying a subject at risk of developing an estrogen-induced cancer and for determining or predicting prognosis for a subject with an estrogen-induced cancer. The methods of the disclosure comprise determining the level of expression of ALPPL2 in a biological sample, typically a blood sample, obtained from a subject. 217-. (canceled) The present disclosure relates generally to methods and protocols for the diagnosis and prognosis of estrogen-induced cancers, in particular endometrial cancer and ovarian cancer.Uterine (endometrial) cancer is the fifth most common gynecological cancer worldwide, with over 60,000 new cases diagnosed and nearly 10,000 deaths every year. The overall 5-year survival of endometrial cancer patients without metastasis ranges from 74% to 91%. However, in case of women with stage IV endometrial cancer, the long-term survival rate drops to 20%. Obesity is an independent risk factor and approximately 50% of cases are associated with high body mass index (BMI, >30 kg/m).Endometrial cancer is most common in post-menopausal women. Early menarche and late menopause, or a long duration of estrogen exposure, can lead to a prolonged growth of endometrium followed by endometrial hyperplasia and cancer. Hypertrophied adipocytes in obese women are a predominant source of the enzyme aromatase, which synthesizes excess in situ estrogen and promotes endometrial adenocarcinomas. Therefore, an elevated level of estrogen is strongly associated with susceptibility to endometrial cancer.Standard treatment for the majority of endometrial cancer patients is major surgery, typically hysterectomy or bilateral salpingo-oophorectomy (fallopian tube and ovary removal). However the five year survival rate for endometrial cancer patients is poor due to the fact the cancer is most often only diagnosed when at an advanced stage.There is a clear need for the identification of biomarkers ...

Подробнее
Номер записи: 83
28-01-2021 дата публикации

Left-Right Gene Expression Signature for Triple Negative Breast Cancer

Номер: US20210025892A1
Автор: RAMSDELL ANN F.
Принадлежит:

Methods and materials are described for use in clinical and research applications directed to cancers. Products include binding arrays, e.g., hybridization or other specific binding arrays, such as genomic or proteomic microarrays. The binding arrays include binding agents developed based upon the recognition of heterogeneity between left-arising and right-arising breast cancer tumors. The arrays can include as binding agents materials that bind transcripts or proteins that are over-expressed in only one of or in both of left-arising or right-arising breast cancer tumors. 1. A method for forming a binding array , comprising:obtaining a first tissue sample from a first subject diagnosed with a breast cancer, the breast cancer diagnosis of the first subject comprising a left breast tumor;determining a first expression level of a first expression product in the first tissue sample;obtaining a second tissue sample from a second subject diagnosed with the breast cancer, the breast cancer diagnosis of the second subject comprising a right breast tumor;determining a second expression level of the first expression product in the second tissue sample;comparing the first expression level with the second expression level;determining that a differential expression level between the first expression level and the second expression level is 2-fold or greater; andimmobilizing a first binding agent for the first expression product or for a gene that encodes the first expression product to a surface of a binding array substrate.2. The method of claim 1 , wherein the breast cancer diagnosis comprises a triple negative breast cancer diagnosis.3. The method of claim 1 , wherein the first expression product comprises a first polynucleotide.4. The method of claim 1 , wherein the first expression product comprises a polypeptide.5. The method of claim 1 , further comprising immobilizing to the surface of the binding array substrate one or more additional binding agents for the first ...

Подробнее
Номер записи: 84
28-01-2021 дата публикации

METHOD FOR DETERMINING THE ANTIOXIDANT CAPACITY OF A BIOLOGICAL SAMPLE AND RELATED KIT

Номер: US20210025897A1
Автор: Moglianetti Mauro, Pompa Pier Paolo
Принадлежит:

A method is provided for determining antioxidant power of a sample of a biological fluid or a food. The method essentially consists in contacting the sample to be tested with an aqueous solution of platinum nanoparticles, an oxidizing agent, and a chromogenic peroxidase substrate, and detecting color of the final solution thus obtained. Color intensity of the solution is proportional to the antioxidant power of the sample. A kit suitable for carrying out the method is also provided. 1. A method for determining antioxidant power of a sample of a biological fluid or a food , comprising the steps of: an aqueous solution of metal nanoparticles, wherein said metal nanoparticles comprise platinum optionally in combination with gold, palladium and/or silver,', 'an oxidizing agent, and', 'a chromogenic peroxidase substrate, and, 'contacting the sample with'}detecting color intensity of a final solution thereby obtained, the color intensity being proportional to the antioxidant power of the biological sample.2. The method of claim 1 , wherein the chromogenic peroxidase substrate is 3 claim 1 ,3′ claim 1 ,5 claim 1 ,5′-tetramethylbenzidine (TMB).3. The method of claim 1 , wherein the oxidizing agent is hydrogen peroxide.4. The method of claim 1 , wherein said metal nanoparticles have a diameter varying within the range of from 0.1 nm to 1000 nm.5. The method of claim 1 , wherein the final solution is prepared in a buffer solution having a pH comprised between 1 and 7.6. The method of claim 1 , wherein the color intensity of the final solution is detected with the naked eye.7. The method of claim 1 , wherein the color intensity of the final solution is detected by UV-visible spectroscopy.8. The method of claim 7 , wherein the color intensity of the final solution is detected by measuring absorbance at a wavelength between about 600 and 700 nm.9. The method of claim 1 , wherein the biological fluid comprises saliva claim 1 , blood claim 1 , sweat and urine.10. The method of ...

Подробнее
Номер записи: 85
04-02-2016 дата публикации

Methods and Compositions for Preventing Metastasis and for Improving the Survival Time

Номер: US20160030367A1
Автор: Ballotti Robert, Cerezo Michael, Rocchi Stephane
Принадлежит:

The invention relates to an AMPK activator (such as for instance metformin) for use in preventing metastasis in a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. The invention also relates to an AMPK activator for use in improving the survival time of a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. 1. An in vitro method for predicting the responsiveness of a patient suffering from a cancer to a prophylactic treatment with an 5′ adenosine monophosphate-activated protein kinase (AMPK) activator suitable for use in preventing metastasis , said method comprising a step of determining the presence of a mutated p53 gene or a mutant form of the p53 protein in a tumor biopsy obtained from said patient , wherein if a mutated p53 gene or a mutant form of the p53 protein is present in said biological sample , then non-response of the patient to the prophylactic treatment with an AMPK activator is indicated , but if a mutated p53 gene or a mutant form of the p53 protein is not present in said biological sample , then a response of the patient to the prophylactic treatment with an AMPK activator is indicated.2. (canceled)3. The method according to claim 1 , wherein the p53 gene mutation leading to said mutated p53 gene or said mutant form of the p53 protein is selected from the group consisting of missense mutations claim 1 , nonsense mutations and frameshift mutations.4. The method according to claim 3 , wherein the missense mutation is a missense mutation affecting residues within the p53 DNA-binding domain.5. The method according to claim 1 , wherein the p53 gene mutation leading to said mutated p53 gene or said mutant form of the p53 protein is a loss-of-function mutation.6. The method according to claim 1 , wherein said mutation is detected by using an amplification assay claim 1 , a hybridation assay claim 1 , by ...

Подробнее
Номер записи: 86
01-02-2018 дата публикации

SYSTEMS AND METHODS FOR MONITORING OF BLOOD LACTATE AND TARGETING OF BLOOD LACTATE VIA NUTRITIONAL SUPPORT

Номер: US20180027862A1
Автор: Brooks George A., Horning Michael A.
Принадлежит: Run Them Sweet LLC

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system. 1. A computer program product comprising a non-transitory computer readable medium having a computer readable program code embodied therein , the product being executable by a processor to perform a method of preventing or treating body wasting in a human patient with traumatic brain injury , the method comprising:receiving a blood lactate concentration of the patient, from a lactate analyzer that has analyzed a blood sample of the patient, the blood lactate concentration received directly from the lactate analyzer or indirectly from the lactate analyzer over a network; andadministering, based on the received blood lactate concentration of the patient, if the blood lactate concentration is less than about 2.0 mM, a nutritional support to the patient.2. The computer program product of wherein the nutritional support comprises a gluconeogenic precursor or a monocarboxylic compound or both.3. The computer program product of wherein the nutritional support comprises one or more salts.4. The computer program product of wherein the nutritional support has a milliosmolality of less than about 1000.5. The ...

Подробнее
Номер записи: 87
29-01-2015 дата публикации

Methods of Treating Serosal Cancer

Номер: US20150030583A1
Автор: Ertem Server A., Moore Malcolm A.S.
Принадлежит: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH

The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy. 110-. (canceled)11. A method to treat serosal cancer in a patient undergoing chemotherapy which comprises administering a hyaluronan synthase inhibitor , a hyaluronidase , a collagenase , or a combination thereof , for a time and in an amount to augment said chemotherapy , or to improve or increase patient survival time , or to cause remission of symptoms ,wherein said chemotherapy comprises administering an effective amount of a compound selected from the group consisting LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A and diphenyleneiodonium chloride, or a combination thereof, to the patient.12. The method of claim 11 , wherein any one of said hyaluronan synthase inhibitor claim 11 , hyaluronidase or collagenase is PEGylated or otherwise modified to increase its half life in vivo.13. The method of claim 11 , wherein said administering a hyaluronan synthase inhibitor claim 11 , a hyaluronidase claim 11 , a collagenase claim 11 , or a combination thereof claim 11 , is done before claim 11 , concurrently with claim 11 , overlapping or after said ...

Подробнее
Номер записи: 88
04-02-2016 дата публикации

CANCER TESTIS ANTIGEN SPERM PROTEIN 17 AS A TARGET FOR BREAST CANCER IMMUNOTHERAPY AND DIAGNOSIS

Номер: US20160030539A1
Автор: Chiriva-Internati Maurizio
Принадлежит:

The present invention includes compositions and methods for treating a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell comprising: identifying a subject in need for treatment for a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell; and administering a therapeutically effective amount of a formulation that leads to the presentation of an immunogenic SP17 protein or peptide antigen on an antigen presenting cell to activate T cells that are SP17-specific T cells, wherein the SP17-specific T cells impair the growth of the breast cancer cell, the metastatic breast cancer cell, or the triple negative breast cancer cell growth. 1. A method for treating a breast cancer cell , a metastatic breast cancer cell , or a triple negative breast cancer cell comprising:identifying a subject in need for treatment for a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell; andadministering a therapeutically effective amount of a formulation that leads to the presentation of an immunogenic SP17 protein or peptide antigen on an antigen presenting cell to activate T cells that are SP17-specific T cells, wherein the SP17-specific T cells impair the growth of the breast cancer cell, the metastatic breast cancer cell, or the triple negative breast cancer cell growth.2. The method of claim 1 , wherein the formulation further comprises an immunogenic SP17 protein or peptide antigen and an adjuvant.3. The method of claim 1 , wherein the formulation is defined further as an antigen presenting cell that has been pre-loaded with the isolated immunogenic SP17 protein or peptide.4. The composition of claim 1 , wherein the formulation is defined further as an antigen presenting cell that expresses an immunogenic SP17 protein or peptide and the antigen presenting cell is defined further as an autologous dendritic cell.5. The composition of claim 1 , wherein the isolated ...

Подробнее
Номер записи: 89
29-01-2015 дата публикации

DIAGNOSTIC AGENT FOR TUMOR

Номер: US20150031013A1
Автор: Abe Fuminori, ISHIZUKA Masahiro, Nakajima Motowo, Ota Urara, Takahashi Kiwamu, Tanaka Tohru
Принадлежит:

It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight. 18.-. (canceled)9. A method for diagnosing a tumor comprising the following steps (a) and (b); {'br': None, 'sup': 2', '1', '3, 'sub': 2', '2', '2, 'RRNCHCOCHCHCOR'}, '(a) orally administering a compound represented by formula (1)'}{'sup': 1', '2', '3, '(wherein Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 24 carbon atoms, an acyl group having 1 to 12 carbon atoms, an alkoxycarbonyl group having 2 to 13 carbon atoms, an aryl group having 6 to 16 carbon atoms, or an aralkyl group having 7 to 22 carbon atoms; Rrepresents a hydroxy group, an alkoxy group having 1 to 24 carbon atoms, an acyloxy group having 1 to 12 carbon atoms, an alkoxycarbonyloxy group having 2 to 13 carbon atoms, an aryloxy group having 6 to 16 carbon atoms, an aralkyloxy group having 7 to 22 carbon atoms, or an amino group) or a salt thereof to a subject at a dose of 1 to 7 mg in terms of 5-aminolevulinic acid per kg of body weight; and'}(b) measuring an amount of ...

Подробнее
Номер записи: 90
29-01-2015 дата публикации

Gravitational fluctuation stress loading method, aircraft, aircraft-flying method, method for promoting serotonin-producing gene expression, serotonin-producing method, method for stimulating central nervous system, and efficacy-measuring method

Номер: US20150031044A1
Автор: Hisashi Ohta, Junichiro Gyotoku, Mitsuhiro Yoshioka, Toshimasa Ochiai
Принадлежит: Mitsubishi Heavy Industries Ltd

A gravitational fluctuation stress loading method capable of causing a new acute stress reaction in a subject or a laboratory animal is provided. A gravitational fluctuation stress loading method including at least one first stress-loading step (S 1 ) of placing a stress load on the subject or the laboratory animal by means of microgravity is provided.

Подробнее
Номер записи: 91
29-01-2015 дата публикации

METHOD FOR PREDICTING AND DETECTING TUMOR METASTASIS

Номер: US20150031744A1
Автор: Cawley Niamh X., Lee Terence K., Loh Yoke Peng, Murthy Saravana Radha Krishna
Принадлежит:

The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-ΔN, and inhibitors of CPE-ΔN and compositions thereof. 1. A method of determining the prognosis of cancer in a subject , the method comprising(a) obtaining a sample from the subject,(b) analyzing the sample for an expression level of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN), and(c) correlating the expression level of CPE-ΔN in the sample to the prognosis of cancer in the subject.2. The method of claim 1 , wherein the prognosis is that the cancer is a metastatic lesion.3. The method of claim 1 , wherein the prognosis is that the cancer is likely to metastasize.4. The method of claim 1 , wherein the prognosis is that the cancer is not a metastatic lesion.5. The method of claim 1 , wherein the prognosis is that the cancer is not likely to metastasize.6. The method of claim 1 , further comprising determining a treatment course for the subject in accordance with the prognosis.7. A method of diagnosing cancer in a subject claim 1 , the method comprising(a) obtaining a sample from the subject,(b) analyzing the sample for an expression level of a carboxypeptidase E (CPE) splice variant that lacks the N terminus (CPE-ΔN), and(c) correlating the expression level of CPE-ΔN in the sample to a diagnosis of cancer in the subject.8. The method of claim 7 , wherein the diagnosis is that the subject has cancer.9. The method of claim 8 , wherein the diagnosis is that the cancer is benign or malignant.10. The method of claim 8 , wherein the diagnosis is that the cancer is metastatic.11. ...

Подробнее
Номер записи: 92
04-02-2016 дата публикации

Amyloidosis-inhibiting Polypeptides and Their Use

Номер: US20160031952A1
Автор: DAGGETT Valerie, HOPPING Gene
Принадлежит:

Isolated polypeptides that possess an a-sheet structure are disclosed that can be used to treat or diagnose amyloid diseases. 1. An isolated polypeptide , comprising 12-23 contiguous amino acids according to the general formula X1-X2-X3-X4-X5 (SEQ ID NO: 1) , whereinX1 is 0-7 contiguous amino acid residues that do not alternate between L and D residues;X2 is 5-9 contiguous amino acid residues alternating between D amino acids and L amino acids;X3 is 0-5 contiguous amino acid residues that do not alternate between L and D residues;X4 is 4-12 contiguous amino acid residues alternating between D amino acids and L amino acids; andX5 is 0-4 contiguous amino acid residues that do not alternate between L and D residues;wherein the isolated polypeptide is not: RGE(m)N(l)S(w)MNEYSGW(t)M(n)L(k)MGR (SEQ ID NO: 2).2. The isolated polypeptide of claim 1 , wherein X1 is 0-2 contiguous amino acid residues that do not alternate between L and D residues.3. (canceled)4. The isolated polypeptide of claim 1 , wherein X2 is 6-8 contiguous amino acid residues alternating between D amino acids and L amino acids.5. The isolated polypeptide of claim 1 , wherein X3 is 1-5 contiguous amino acid residues that do not alternate between L and D residues.68.-. (canceled)9. The isolated polypeptide of claim 1 , wherein X4 is 6-12 contiguous amino acid residues alternating between D amino acids and L amino acids.10. The isolated polypeptide of claim 1 , wherein X5 is 0-3 contiguous amino acid residues that do not alternate between L and D residues.1112.-. (canceled)13. The isolated polypeptide of claim 1 , wherein at least one of the following is true:(a) X1 is 0 or 1 amino acid;(b) X2 is 5, 6, 8, or 9 contiguous amino acid residues alternating between D amino acids and L amino acids;(c) X3 is 0-4 contiguous amino acid residues that do not alternate between L and D residues;(d) X4 is 6, 8, 9, 10, 11, or 12 contiguous amino acid residues alternating between D amino acids and L amino acids; or(e) X5 ...

Подробнее
Номер записи: 93
04-02-2016 дата публикации

Glycine, Mitochondrial One-Carbon Metabolism, and Cancer

Номер: US20160032401A1
Автор: JAIN Mohit, Mootha Vamsi K., Nilsson Roland
Принадлежит: The General Hospital Corporation

Methods of treatment, diagnosis, and determining prognosis of subjects with cancer, generally comprising determining levels of glycine metabolism or a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2, MTHFD1L, or MTHFD2, and optionally administering an antifolate or an agent that inhibits a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2 or MTHFD2. 1. A method of treating a cancer in a subject , the method comprising:obtaining a sample comprising tumor cells from the subject;determining a level of one or more of glycine consumption in the sample;comparing the level of glycine consumption in the sample to a reference level of glycine consumption;selecting a subject who has a level of glycine consumption above the reference level; andtreating the subject by administering a therapeutically effective amount of an antifolate drug.2. The method of claim 1 , wherein the antifolate drug is methotrexate.3. The method of claim 1 , wherein the antifolate drug is linked covalently to a mitochondrial targeting moiety.4. The method of claim 1 , wherein the level of glycine consumption is determined by imaging a tumor in a living subject using a labeled substrate claim 1 , e.g. claim 1 , C-glycine.5. The method of claim 4 , comprising imaging a tumor in a living subject using PET6. A method of treating a cancer in a subject claim 4 , the method comprising:obtaining a sample comprising tumor cells from the subject;determining a level of one or more of SHMT2, MTHFD2, and/or MTHFD1L protein, mRNA, or activity in the sample;comparing the level of SHMT2, MTHFD2, and/or MTHFD1L protein, mRNA, or activity in the sample to a reference level of SHMT2, MTHFD2, and/or MTHFD1L protein, mRNA, or activity;selecting a subject who has a level of SHMT2, MTHFD2, and/or MTHFD1L protein, mRNA, or activity above the reference level; andtreating the subject by administering a therapeutically effective amount of one or both of an antifolate drug and an agent that inhibits a ...

Подробнее
Номер записи: 94
02-02-2017 дата публикации

NONINVASIVE DETECTION OF CANCER ORIGINATING IN TISSUE OUTSIDE OF THE LUNG USING EXHALED BREATH

Номер: US20170030892A1
Автор: Bousamra Michael, Fu Xiaoan, Nantz Michael, van Berkel Victor
Принадлежит:

Provided is a non-invasive method of detecting or screening for a cancer in a subject specimen originating in a tissue outside of the lung. The method includes detecting elevated levels of one or more carbonyl-containing volatile organic compounds (VOCs) that are biomarkers for the cancer in exhaled breath from the subject specimen. The method may further include obtaining exhaled breath from the subject specimen; forming adducts of the carbonyl-containing VOCs with a reactive chemical compound; quantifying the adducts of the carbonyl-containing VOCs to establish a subject value for each of the adducts; and comparing each subject value to a threshold healthy specimen value for each of the adducts of the carbonyl-containing VOCs. One or more subject values at quantities greater than threshold healthy specimen values are also useful for screening for the cancer in the subject specimen. 1. A non-invasive method of detecting a cancer disease state in a subject specimen wherein the primary cancer originates in a tissue outside of the lung , the method comprising the steps of:obtaining exhaled breath from the subject specimen, wherein the exhaled breath includes a plurality of carbonyl-containing volatile organic compounds (VOCs);forming adducts of the plurality of carbonyl-containing VOCs with a reactive chemical compound;quantifying each of the adducts of each of the plurality of carbonyl-containing VOCs to establish a subject value for each of the adducts; andcomparing each subject value to a threshold healthy specimen value for each of the adducts of the plurality of carbonyl-containing VOCs, the threshold healthy specimen value corresponding to a value calculated from healthy specimens, in order to determine the presence of one or more subject values at quantities greater than their respective threshold healthy specimen values, thereby indicating a substantial likelihood of a cancer disease state in the subject specimen.2. The method of claim 1 , wherein the cancer ...

Подробнее
Номер записи: 95
02-02-2017 дата публикации

USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS

Номер: US20170030935A9
Автор: Bowen Benjamin P., LOUIE Katherine B., NORTHEN Trent R.
Принадлежит:

Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. 1. A method for identifying one or more diseased cells in a subject , comprising:(a) providing a biological sample derived from a subject;(b) analyzing the biological sample by mass spectrometry; and(c) determining the abundance of one or more lipids in the biological sample, wherein an altered abundance of the one or more lipids in the biological sample, as compared to a reference level, indicates a presence of one or more diseased cells in the subject from which the biological sample is derived.2. The method of claim 1 , wherein the reference level is established using a reference sample from a healthy subject.3. (canceled)4. (canceled)5. The method of claim 1 , wherein the biological sample comprises a tissue sample claim 1 , a bodily fluid claim 1 , a cell culture or extracts thereof claim 1 , or a combination thereof.6. (canceled)7. (canceled)8. The method of claim 1 , wherein the biological sample comprises one or more lipid-containing microparticles.9. The method of claim 8 , wherein the one or more lipid-containing microparticles are exosomes claim 8 , cell membrane fragments claim 8 , cellular and intracellular organelle fragments claim 8 , lipid bilayers claim 8 , or a combination thereof.10. (canceled)11. (canceled)12. The method of claim 8 , wherein analyzing the biological sample by mass spectrometry comprises isolating the one or more lipid-containing microparticles from the biological sample and analyzing the lipid-containing microparticles by mass spectrometry.13. The method of claim 12 , wherein the isolating step comprises isolating the one or more lipid-containing microparticles from the biological sample by filtration claim 12 , centrifugation claim 12 , microfluidics claim 12 , antibody affinity capture claim 12 , or a ...

Подробнее
Номер записи: 96
04-02-2016 дата публикации

BIOLOGICAL SPECIMEN EVALUATION METHODS USING CYTOLOGY AND IMMUNOLOGY

Номер: US20160033482A1
Автор: DOMANIK Richard A., JOLLEY Michael E.
Принадлежит:

Information on cytokines and cytology obtained from a biological specimen are combined as a method of predicting the risk that dysplasia will progress to cancer. Methods are disclosed herein to augment the evaluation of biological samples from subjects being tested for cancer. In addition to the cell types that are traditionally considered in the morphology-based cytological screening of specimens, methods disclosed herein add evaluations of certain cell types and cytokines that are traditionally discounted or ignored during screening. 1. A method for estimating the risk of dysplasia progressing to cancer in a subject , the method comprising:(a) detecting and classifying dysplastic cells in a cytological preparation from a biological sample from the subject;(b) detecting the presence of anti-inflammatory cytokines in dysplastic or non-dysplastic cells; and(c) estimating the risk of dysplasia progressing to cancer in the subject based upon whether at least one anti-inflammatory cytokine is present in dysplastic or in other cells detected in the specimen; wherein no expression by any cells indicates low risk, expression by non-dysplasitic cells indicates moderate risk and expression by dysplastic cells indicates high risk.2. The method of wherein the anti-inflammatory cytokine is IL-10.3. The method of wherein dysplastic cells are stained with one or more fluorogenic stains and detected and classified on the basis of cell morphology.4. The method of wherein T-cells claim 1 , B-cells claim 1 , macrophages and/or other cells of the innate immune system are optionally detected and classified.5. A method for the immunological determination of the spatial distribution of an analyte in a cytological or histological specimen claim 1 , wherein the detection reagents comprise an antibody bearing a first label claim 1 , and separately a second label claim 1 , the method comprising:(a) contacting the specimen with the antibody labeled separately with different labels that are ...

Подробнее
Номер записи: 97
04-02-2016 дата публикации

Compositions and methods for cancer diagnosis

Номер: US20160033485A1
Автор: Arthur PRINDLE, Jeff HASTY, Sangeeta N. Bhatia, Tal DANINO
Принадлежит: HOWARD HUGHES MEDICAL INSTITUTE, Massachusetts Institute of Technology, UNIVERSITY OF CALIFORNIA

The present disclosure provides compositions comprising a food product, non-pathogenic microorganism, kits, methods of diagnosing a tumor in a subject, methods of quantifying the number of cancer cells in a cell sample, and methods of detecting a cancer cell, cancer tissue, or cell associated with a hyperproliferative disorder. In some embodiments, the method comprises a step of detecting the presence or absence of a modified substrate or portion thereof in urine of an animal without an instrument and solely by visual inspection of the urine.

Подробнее
Номер записи: 98
04-02-2016 дата публикации

USE OF ACY-1 AS A MARKER OF ISCHAEMIA/REPERFUSION, DELAYED GRAFT FUNCTION AND GRAFT VIABILITY AS WELL AS METHOD THEREOF

Номер: US20160033507A1
Автор: Banks Rosamonde Elizabeth, Lewington Andrew, Selby Peter John, Smith Matthew Peter Welberry
Принадлежит:

The invention relates to use of ACY-1 as a biomarker for ischaemia-reperfusion injury. 1. Use of ACY-1 as a biomarker for ischaemia-reperfusion injury.2. The use according to wherein said ischaemia-reperfusion injury is in at least one tissue selected from brain claim 1 , heart claim 1 , kidney claim 1 , lung and liver.3. The use according to or claim 1 , wherein said ischaemia-reperfusion injury is caused by myocardial infarction claim 1 , stroke or organ transplantation.4. The use according to claim 1 , wherein said ischaemia-reperfusion injury results in delayed graft function in a post operative organ transplant patient.5. The use according to claim 4 , wherein said post operative organ transplant patient is post operative renal transplant patient.6. Use of ACY-1 as a biomarker for delayed graft function.8. The method according to wherein said ischaemia-reperfusion injury is in at least one tissue selected from brain claim 7 , heart claim 7 , kidney claim 7 , lung and liver.9. The method according to or claim 7 , wherein said ischaemia-reperfusion injury is caused by myocardial infarction claim 7 , stroke or organ transplantation.10. The method according to claim 7 , wherein said patient is a post operative renal transplant patient.12. The method according to claim 11 , wherein said patient is a post operative renal transplant patient.14. A method of determining a fluid management strategy for a post operative renal transplant patient claim 11 , comprising:i) determining the level of ACY-1 in a sample isolated from the patient; andii) comparing the level of ACY-1 in the patient sample with the level of ACY-1 in a control sample or with a predetermined reference level for ACY-1, wherein an increased level of ACY-1 in the patient sample compared to the control sample or compared to the predetermined reference level identifies that the patient requires a reduced amount of fluid compared to that normally administered to a post-operative renal transplant patient, or ...

Подробнее
Номер записи: 99
04-02-2016 дата публикации

2-HYDROXYGLUTARATE AS A BIOMARKER FOR CHRONIC HYPOXIA

Номер: US20160033533A1
Автор: Thompson Craig B., Ward Patrick S., WISE David R.
Принадлежит:

The present invention provides biomarkers for sensitive, specific, accurate and quantitative diagnosis and assessment of chronic hypoxia. In particular, the present invention provides 2-hydroxyglutarate as a biomarker that is differentially produced in chronic hypoxia. Furthermore, embodiments of the invention are able to differentiate between chronic and acute hypoxia. Assays for levels of 2-hydroxyglutarate may be used alone or in conjunction with additional biomarkers of hypoxia to increase the precision of analysis. In particular embodiments of the invention, the level of 2-hydroxyglutarate and at least one second biomarker may be assayed to generate a hypoxic profile that can be compared to a reference or control profile, thereby diagnosing a subject as normoxic, chronically hypoxic, or acutely hypoxic. 1. A method of diagnosing chronic hypoxia in a subject , comprising steps of:measuring a level of at least one biomarker in a sample from the subject, wherein the at least one biomarker comprises 2-hydroxyglutarate; andcomparing the measured level with a control level representative of acute hypoxia or normoxia, where chronic hypoxia is diagnosed when the measured level shows a significant difference from the control level.2. The method of claim 1 , further comprising a step of managing treatment of the subject based on the determination of chronic hypoxia.3. The method of claim 2 , further comprising a step of measuring the at least one biomarker after the step of managing.4. The method of claim 1 , wherein the step of measuring comprises:measuring levels of at least two biomarkers in a sample from the subject, wherein one of the at least two biomarkers is 2-hydroxyglutarate; andthe method further comprises a step of comparing the measured levels with control levels representative of acute hypoxia or normoxia, where chronic hypoxia is diagnosed when the measure level shows a significant difference from the control levels.5. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 100